Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
- Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
- 09/24/2025
|
Trump links autism to Tylenol ingredient use during pregnancy — here's what to know
- The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol. CNBC's Angelica Peebles explains.
- 09/24/2025
|
Tylenol maker Kenvue rebounds after Trump spreads unproven claims
- Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and, in some cases, discredited ties between Tylenol, vaccines, and autism.
- 09/23/2025
|
How Trump is spreading unproven information about Tylenol, autism, and vaccines
- President Donald Trump on Monday used the platform of the presidency to promote unproven and in some cases discredited ties between Tylenol, vaccines and autism as his administration announced a wide-ranging effort to study the causes of the complex brain disorder.“Don't take Tylenol,” Trump instructed pregnant women around a dozen times during the unwieldy White House news conference, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.
- 09/23/2025
|
Pharmaceutical Stock Bounces Off Record Lows
- Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of acetaminophen -- the active ingredient of the company's Tylenol pain drug -- in pregnancy and autism.
- 09/23/2025
|
Tylenol: Kenvue's Sobering Reality
- I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.
- 09/23/2025
|
QUOTE BOX Global reaction to Trump's unproven claim about Tylenol's link to autism
- U.S. President Donald Trump on Monday linked autism to childhood vaccines and the use of popular pain medication Tylenol by women when pregnant, elevating claims not backed by scientific evidence to the forefront of U.S. health policy.
- 09/23/2025
|
Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism
- CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on the Trump administration's announcement linking acetaminophen taken during pregnancy to autism.
- 09/23/2025
|
KVUE Rebounds Against Trump Admin, BA International Boost, AZO Earnings Miss
- Kenvue (KVUE) rallied Tuesday morning despite the Trump administration linking Tylenol to autism. Diane King Hall notes that analyst commentary may have helped the stock's upward trajectory.
- 09/23/2025
|
Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
- 23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
- 09/23/2025
|
Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autism
- 23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
- 09/23/2025
|
Trump admin draws unproven link between autism and Tylenol ingredient use during pregnancy
- The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol.
- 09/23/2025
|
Kenvue bounces after Trump's Tylenol remarks spark sell-off
- After a bruising session on Monday, Kenvue Inc (NYSE:KVUE) shares staged a 6% rebound in premarket trade on Tuesday, clawing back much of the previous day's 7.5% drop. The rally came after President Donald Trump repeatedly told pregnant women to avoid Tylenol, reviving disputed claims of a link between the painkiller and autism.
- 09/23/2025
|
Kenvue Stock Bounces Back After Trump Links Tylenol to Autism. Here's Why.
- “Independent, sound science clearly shows that taking acetaminophen does not cause autism,” a Kenvue spokesperson told Barron's.
- 09/23/2025
|
Wall Street Breakfast Podcast: Kenvue In Focus
- Kenvue (KVUE) rebounds 6% premarket after sharp drop, following FDA warning on acetaminophen use during pregnancy and company defense of Tylenol's safety. Boeing (BA) secures Uzbekistan Airways' largest-ever order for up to 22 Dreamliners, supporting fleet modernization and international route expansion.
- 09/23/2025
|
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism link
- Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.
- 09/23/2025
|
Tylenol-maker Kenvue shares bounce, Trump claims face pushback
- Tylenol-maker Kenvue stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.
- 09/23/2025
|
Kenvue is bracing for an explosion of litigation over its popular pain reliever Tylenol after the Trump administration warned that the drug's active ingredient is a potential cause of autism
- The Trump administration warned about the risk of use during pregnancy, which the company disputes.
- 09/22/2025
|
Final Trade: AAPL, C, PFE, KVUE
- The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
- 09/22/2025
|
Kenvue Stock Sinks Ahead of Trump Announcement Tying Autism to Tylenol Use During Pregnancy
- Shares of Tylenol maker Kenvue (KVUE) dropped Monday ahead of an anticipated report by the Trump administration linking pregnant women's use of the painkiller to autism.
- 09/22/2025
|
Here's what to know about Tylenol use during pregnancy in light of President Trump's recent remarks
- The Trump administration said acetaminophen could cause autism. Doctors maintain it is safe during pregnancy.
- 09/22/2025
|
Trump admin draws unproven link between autism and Tylenol ingredient use during pregnancy
- The Trump administration drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol. Officials warned pregnant women against using acetaminophen early on unless they have a fever, and touted a lesser-known drug, leucovorin, as a potential treatment for symptoms of autism.
- 09/22/2025
|
KVUE stock price: Kenvue plummets as Trump announcement expected to tie Tylenol to autism, tout leucovorin
- Shares of Kenvue Inc. (KVUE), the parent company of Tylenol, are down around 6% in midday trading on Monday on news the Trump administration is expected to link the over-the-counter pain relief medicine to autism.
- 09/22/2025
|
Trump 'to link paracetamol use to autism' - here's what the evidence says
- Donald Trump is reportedly expected to claim there is a link between the use of paracetamol in pregnancy and the development of autism - but what does the evidence say?
- 09/22/2025
|
Kenvue says Tylenol is safe, but stock hits record low ahead of Trump speech
- Kenvue's stock was heading for a record low as investors express concerns over what President Trump will say regarding the use of acetaminophen — the active ingredient in Tylenol — and the autism epidemic.
- 09/22/2025
|
Top Stock Movers Now: Nvidia, Apple, Kenvue, and More
- Major U.S. equities indexes climbed Monday afternoon, boosted by the tech sector as Nvidia (NVDA) announced a $100 billion investment in ChatGPT maker OpenAI to build out AI data centers.
- 09/22/2025
|
Kenvue stock sinks to record low as Trump to reportedly link Tylenol use to autism
- Shares of Kenvue, the consumer-health spinoff of Johnson & Johnson, tumbled 7.1% to a record low of $17.03 on Monday with the selloff coming ahead of US President Donald Trump's planned announcement that use of Tylenol — Kenvue's top-selling pain reliever — during pregnancy could contribute to autism risk, according to reports.
- 09/22/2025
|
Canaccord Genuity's Anderson: Kenvue sell-off ‘unwarranted,' stock looks like a buying opportunity
- Kenvue shares tumbled more than 7% after reports that the Trump administration may link Tylenol use during pregnancy to autism risk. Canaccord Genuity analyst Susan Anderson joins 'Money Movers' to share her outlooks on the stock.
- 09/22/2025
|
Trump expected to link autism with Tylenol, experts say more research needed
- President Donald Trump is expected to give a Monday afternoon announcement linking the use of popular over-the-counter pain medication Tylenol to the development of autism during pregnancy, a claim which many doctors dispute.
- 09/22/2025
|
Trump administration reportedly plans to link autism to Tylenol use during pregnancy
- Angelica Peebles joins 'Squawk on the Street' with the latest news.
- 09/22/2025
|
Kenvue Shares Fall on Report That White House Plans to Link Tylenol to Autism Risk
- Shares of Tylenol maker Kenvue (KVUE) are dropping in morning trading on a report that the White House is expected to make an announcement Monday linking pregnant women's use of the painkiller to increased risk of autism.
- 09/22/2025
|
Trump to Announce Link Between Tylenol and Autism. Kenvue Stock Slumps.
- Tylenol maker Kenvue ‘strongly disagrees' there is a causal link between acetaminophen use during pregnancy and autism.
- 09/22/2025
|
Kenvue takes a $1.4bn Tylenol hit
- Kenvue Inc (NYSE:KVUE) shares dropped 4% at the open on Monday, erasing about $1.4 billion in market value, after a report that Trump administration officials plan to warn pregnant women against taking Tylenol unless they have a fever. The Washington Post said the guidance will claim the active ingredient, acetaminophen, is linked to autism, citing unnamed sources.
- 09/22/2025
|
Trump administration reportedly plans to link autism to Tylenol use during pregnancy
- The Trump administration is expected to make an announcement Monday linking pregnant women's use of Tylenol to autism, according to The Washington Post. Federal health officials will also reportedly highlight leucovorin as a potential autism treatment.
- 09/21/2025
|
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
- Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
- 09/12/2025
|
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
- Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
- 09/12/2025
|
Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports
- Kenvue's interim Chief Executive Officer Kirk Perry met Robert F. Kennedy Jr. to try and dissuade the U.S. health secretary from including Tylenol as a potential cause of autism in an upcoming report, the Wall Street Journal said on Friday, citing a person familiar with the matter.
- 09/12/2025
|
Dividend Kings: 2 Ideal Buys In 25 "Safer" Of 56 September Dogs
- The Dividend Kings list now includes 56 stocks, but only a select few offer fair value and strong yields relative to share price. Five top-yielding Dividend Kings—UVV, CDUAF, NWN, UBSI, and KVUE—currently meet my ideal of annual dividends exceeding share price. Analyst targets suggest these top-yield Kings could deliver net gains of 16% to 75% by September 2026, with lower volatility than the market.
- 09/10/2025
|
Explainer: Is Tylenol safe to take during pregnancy?
- U.S. Health Secretary Robert F. Kennedy Jr. plans to announce a link between autism and prenatal exposure to the popular over-the-counter pain and fever medicine Tylenol, sold generically as acetaminophen in the United States and paracetamol in the UK, the Wall Street Journal reported on Friday.
- 09/05/2025
|
Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol
- Dr. Scott Gottlieb, fmr. FDA commissioner, joins 'Fast Money' with reaction to RFK Jr. implying Tylenol usage is linked to autism, sending Kenvue stock plummeting.
- 09/05/2025
|
Kenvue fights back against Tylenol safety concerns as its stock tumbles
- Kenvue rushed to the defense of Tylenol, but the stock still suffered a record selloff on news that RFK Jr. will release a report linking the use of acetaminophen during pregnancy to autism.
- 09/05/2025
|
Tylenol Maker Kenvue's Stock Slumps Following Report RFK Jr. Will Link It to Autism
- Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.
- 09/05/2025
|
Tylenol-maker shares sink after report says RFK's HHS will link to autism
- Shares in the the parent company of Tylenol-maker McNeil Consumer Healthcare sank after a report suggested Robert F. Kennedy Jr.'s HHS will name the drug as a potential cause of autism.
- 09/05/2025
|
RFK Jr. Report Will Link Autism To Tylenol Use During Pregnancy, Report Says
- A promised report from Health and Human Services Secretary Robert F. Kennedy Jr. will claim the use of the common painkiller Tylenol during pregnancy is a potential cause for autism, The Wall Street Journal reported, while the drug's maker maintains the drug's safety.
- 09/05/2025
|
RFK Jr. To Link Tylenol Use To Autism: Report
- Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.
- 09/05/2025
|
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy
- Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy
- 09/05/2025
|
Kennedy and HHS to link use of Tylenol use in pregnancy to autism, WSJ reports
- U.S. Health Secretary Robert F. Kennedy Jr. plans to announce that use of over-the-counter pain medication Tylenol in pregnant women is potentially linked to autism in a report that will also suggest a medicine derived from folate can be used to treat symptoms of the disorder in some people, The Wall Street Journal reported on Friday, citing people familiar with the matter.
- 09/05/2025
|
Kenvue Can't Be Written Off Yet
- Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board, new leadership, and new strategy suggest real change is on the way for a business where execution clearly is a concern.
- 08/18/2025
|
Kenvue attracts share purchase by activist investor Sachem Head
- Band-Aid and Tylenol maker Kenvue attracted the attention of another activist investor in the second quarter, with Sachem Head Capital Management reporting that it bought into the stock.
- 08/14/2025
|
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
- Kenvue, Inc. (NYSE:KVUE ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amit Banati - Chief Financial Officer Kirk L. Perry - Interim CEO & Director Sofya Tsinis - Head of Investor Relations Conference Call Participants Andrea Faria Teixeira - JPMorgan Chase & Co, Research Division Bonnie Lee Herzog - Goldman Sachs Group, Inc., Research Division Filippo Falorni - Citigroup Inc., Research Division Javier T.
- 08/07/2025
|
Kenvue misses Q2 sales estimates, cuts 2025 profit forecast
- Kenvue Inc (NYSE:KVUE) reported second quarter sales below Wall Street expectations, while also downwardly revising its full-year profit forecast. The Neutrogena, Aveeno, Tylenol and Band-Aid owner reported net sales were down 4%, driven by weaker allergy and sun season demand in North America and shipment timing changes in China.
- 08/07/2025
|
Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/07/2025
|
Kenvue (KVUE) Q2 Earnings Top Estimates
- Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.
- 08/07/2025
|
Kenvue meets profit estimates amid strategic review
- Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic review at the consumer health company.
- 08/07/2025
|
Kenvue Reports Second Quarter 2025 Results
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value,” said Kirk Perry, Interim Chief Executive Officer. “I'm thrilled to take on this new role at such an important time for the Company.
- 08/07/2025
|
Should You Buy Kenvue Stock At $22?
- Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental weaknesses that render the stock unattractive for new investors at this time.
- 08/05/2025
|
Countdown to Kenvue (KVUE) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
- Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
- 08/04/2025
|
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
- Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2025
|
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
- Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
- 07/30/2025
|
Kenvue Increases Quarterly Cash Dividend
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century.
- 07/30/2025
|
20 Kiplinger July Dividend Favorites: No Cigars
- Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to deliver 9-20% net gains by July 2026, with average risk 40% below the market. Many high-yield favorites are not 'safer' due to negative free cash flow, so investors should seek price pullbacks or focus on cash-rich, fair-priced stocks.
- 07/27/2025
|
Kenvue to Announce Second Quarter 2025 Results on August 7, 2025
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made availa.
- 07/25/2025
|
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.
- The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend stocks.
- 07/15/2025
|
Kenvue announces CEO transition and strategic review
- Kenvue (NYSE:KVUE) has announced a CEO transition and the launch of a strategic review process aimed at enhancing shareholder value and improving the long-term performance of the consumer health company. Kirk Perry, a Kenvue director with more than 30 years of experience in the consumer goods and technology sectors, has been appointed interim CEO, effective immediately.
- 07/14/2025
|
Call Traders Circle Tylenol Parent Amid C-Suite Swap
- Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance.
- 07/14/2025
|
Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales
- Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down. Kenvue shares were up by more than 6% during pre-market on the back of the announcement.
- 07/14/2025
|
Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.
- The company, formerly part of Johnson & Johnson, says it is taking steps ‘to accelerate profitable growth.'
- 07/14/2025
|
Kenvue CEO steps down
- Tylenol maker Kenvue said on Monday Thibaut Mongon had stepped down as chief executive officer and board member.
- 07/14/2025
|
Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. “Kenvue has world-class brands in attractive categories and a strong global platform. The actions announced today are to ensure we have the right talent,.
- 07/14/2025
|
Looking to Generate Passive Income? Consider These 3 Rock-Solid Dividend King Stocks
- Investing in the stock market over a long-term time horizon can be an excellent way to compound your savings. However, the path toward unlocking significant gains can be marked by numerous ups and downs.
- 07/09/2025
|
Buy 3 IDEAL Dividend Kings Of 25 'Safer' In July's 55
- Most Dividend Kings are overpriced, but six currently offer fair value, with annual dividends from $1,000 invested exceeding their share prices. Top-yielding Dividend Kings like Altria, Northwest Natural, and United Bankshares meet my 'dogcatcher ideal' for income-focused investors. Analyst forecasts suggest select Dividend Kings could deliver 13-28% total returns by July 2026, with lower volatility than the market.
- 07/04/2025
|
The 3 Best Dividend Aristocrats Under $25 to Buy Now With $1000
- For younger investors or those on a tight budget, investing in stocks to generate consistent passive income can be daunting because many top dividend stocks trade at prices ranging from $25 to over $100 per share.
- 06/29/2025
|
69 June Aristocrats: 1 To Buy
- Five of the ten lowest-priced S&P 500 Dividend Aristocrats are currently attractive buys, offering high yields and fair valuations for income investors. Analyst forecasts suggest potential net gains of 15.65% to 36.53% for the top ten Aristocrat Dogs by June 2026, with average risk below the market. Fifteen Aristocrats show negative free cash flow margins, signaling caution—dividends may not be sustainable for these cash-poor stocks.
- 06/20/2025
|
Kenvue takeover speculation heats up ahead of M&A window
- Kenvue Inc (NYSE:KVUE) is again at the center of takeover speculation as the August expiration of its post–spin-off tax agreement with Johnson & Johnson (NYSE:JNJ) approaches, potentially clearing the way for a sale. Despite concentration and uneven performance, Kenvue's brand lineup is attractive, according to analysts at Jefferies.
- 06/16/2025
|
Kenvue considering sale of skin and beauty brands to streamline portfolio: report
- Kenvue Inc (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson (NYSE:JNJ) in 2023, is considering selling a selection of its smaller skin health and beauty brands to streamline this segment and refocus on its core products, according to a Reuters report. The report, which cited four people with knowledge of the matter, is considering the sale of brands such as Clean & Clear, Maui Moisture, Neostrata, its German baby care brand Bebe, and Japanese brand Dr.Ci:Labo.
- 06/13/2025
|
Kenvue mulls sale of some skin health and beauty brands, sources say
- Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment to focus on core products.
- 06/12/2025
|
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Kenvue Inc. and Encourages Long-Term Kenvue Investors to Contact the Firm - KVUE
- PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Kenvue Inc. (NYSE:KVUE) on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/kenvue/ Recently a securities fraud complaint was filed against Kenvue on behalf of investors who purchased or acquired shares of the company's stock between May 8, 2023 and September 12, 2023.
- 06/09/2025
|
Kenvue: Steady Consumer Health Play; Initiate With 'Buy'
- I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience and ongoing margin expansion through cost efficiencies. Short-term headwinds from China destocking and tariffs are manageable, with long-term organic growth expected to normalize at 4.5%.
- 06/04/2025
|
June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
- Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, and Canadian Utilities—meet the ideal 'dogcatcher' standard for fair pricing and dividend safety. Analyst projections suggest select Dividend Kings could deliver up to 58% total returns by June 2026, with lower volatility than the market overall.
- 06/04/2025
|
Kenvue Debuts on Fortune 500 List
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science.
- 06/02/2025
|
5 Rock-Solid Dividend Stocks Under $50 With Room to Run
- Looking for high-yield dividend stocks below $50? Here are the top five.
- 05/29/2025
|
Give Your Portfolio A Little Stability And Income Reliability During This Market Uncertainty
- Market uncertainty and muted returns in 2025 make portfolio stability and income reliability crucial; dividend stocks are key for navigating volatility. General Mills offers a well-covered 4.4% yield, strong fundamentals, and attractive long-term value despite near-term headwinds and potential price weakness. Kenvue, with a 3.4% yield and resilient performance post-spin-off, provides stability and potential for gradual dividend growth and price appreciation.
- 05/28/2025
|
Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m.
- 05/21/2025
|
69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs
- Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten Aristocrat Dogs could deliver 16% to 38% net gains by May 2026, with average risk below the market. Caution: Fourteen Aristocrats have negative free cash flow margins, making their dividends less secure despite high yields—focus on 'safer' picks like Hormel.
- 05/20/2025
|
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
- Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple and Johnson & Johnson hold Moody's highest credit rating of Aaa, reflecting exceptional financial strength and stability. Alphabet and Berkshire Hathaway are rated Aa2 by Moody's, indicating very high credit quality, just below the top tier.
- 05/19/2025
|
Third Point details stakes in U.S. Steel, Kenvue in filing
- Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the size of its stakes in U.S. Steel and Kenvue , companies that shareholders hope will soon benefit from being bought by someone.
- 05/15/2025
|
Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. today announced its global efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative.
- 05/14/2025
|
Kenvue: First Quarter A Sign Of Challenging Times, But Still A Solid Long-Term Play
- Kenvue, a solid dividend-paying stock spun off from Johnson & Johnson, offers long-term upside despite current economic challenges and declining consumer sentiment. Recent earnings showed slight revenue growth, but declines in organic sales and margins, impacted by currency headwinds and destocking in China. Management remains optimistic with 2025 guidance expecting 2%-4% organic sales growth, supported by cost-cutting, marketing, and AI collaboration with Microsoft.
- 05/11/2025
|
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
- Kenvue, Inc. (NYSE:KVUE ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director Paul Ruh - Chief Financial Officer Conference Call Participants Bonnie Herzog - Goldman Sachs Peter Grom - UBS Andrea Teixeira - J.P. Morgan Anna Lizzul - Bank of America Keith Davis - Jefferies Nik Modi - RBC Capital Markets Filippo Falorni - Citi Javier Escalante - Evercore ISI Alec Legg - Canaccord Genuity Steve Powers - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Hello, and welcome to the Kenvue First Quarter 2025 Earnings Conference Call.
- 05/08/2025
|
Compared to Estimates, Kenvue (KVUE) Q1 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Kenvue (KVUE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 05/08/2025
|
Kenvue Boosts 2025 Sales Growth View
- The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, while warning that foreign exchange would weigh on adjusted earnings.
- 05/08/2025
|
Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates
- Kenvue (KVUE) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.28 per share a year ago.
- 05/08/2025
|
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
- Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.
- 05/08/2025
|
Kenvue stock climbs as second quarter comes in ahead of forecasts
- Consumer brands firm Kenvue Inc (NYSE:KVUE) traded on the front foot in Thursday's early deals, as its second quarter beat expectations (but, fell short in year-over-year comparatives). Net sales totalled $3.74 billion in Kenvue's first quarter, exceeding the consensus forecast of $3.68 billion whilst 3.9% lower than last year's digit.
- 05/08/2025
|
Kenvue first-quarter results beat estimates on strength in self care unit
- Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a fall in demand for its skin health and beauty products.
- 05/08/2025
|
Kenvue Announces Chief Financial Officer Transition
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a.
- 05/08/2025
|
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
- The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kings, including Altria and Canadian Utilities, are now fairly priced, with annual dividends from $1K investments exceeding their single-share prices. Analysts predict net gains of 14.7% to 56.86% for the top ten Dividend Kings by yield for the coming year, based on target prices. Among the 55 Dividend Kings, 16 show negative free cash flow margins, making them cash-poor and unsafe for investment.
- 05/06/2025
|
Ahead of Kenvue (KVUE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Kenvue (KVUE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
- 05/05/2025
|
3 Dividend Stocks You Can Be Comfortable Buying and Holding, Even in a Recession
- The broader stock market indexes have recovered nicely in recent weeks. However, some investors may still fear that the impact of tariffs could lead the economy into a recession, which could have longer-lasting effects on earnings and stock prices.
- 05/04/2025
|
2 Stocks Down 89% and 15% to Buy Right Now
- A third of the year is now over, and the stock market has seen incredible levels of volatility across the stretch. The S&P 500 index is down roughly 9.5% from its high as of this writing, and the Nasdaq Composite index has fallen 13.5%.
- 05/02/2025
|
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2025
|
Loeb's Third Point builds stake in Band-Aid maker Kenvue
- Billionaire investor Daniel Loeb's hedge fund Third Point is building a stake in Kenvue , sources familiar with the matter said on Friday, as some investors are pushing for strategic changes at the consumer healthcare company.
- 04/25/2025
|
5 Rock-Solid Passive Income Dividend Aristocrats That Are Reasonably Safe From Tariffs
- The driving force behind the recent volatility in the stock and bond markets can be boiled down to one specific item: the threat of tariffs and a global trade war.
- 04/25/2025
|
Kenvue to Announce First Quarter 2025 Results on May 8, 2025
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after.
- 04/24/2025
|
Two Stocks To Consider During Market Unrest To Provide Income Stability
- Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.
- 04/22/2025
|
Kenvue Declares Quarterly Cash Dividend
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®.
- 04/16/2025
|
Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations
- SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue announced a five-year collaboration with Microsoft to transform digital operations through Artificial Intelligence (AI) technologies.
- 04/16/2025
|
2 Under-the-Radar Consumer Staples Stocks With Big Dividends
- During volatile markets, investors seek safety and defense in the consumer staples sector as necessities like food, health and hygiene products become the top priorities.
- 04/15/2025
|
KENVUE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Kenvue Inc. (NYSE: KVUE) and Encourages Long-Term KVUE Investors to Contact the Firm
- PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Kenvue Inc. (NYSE: KVUE) on behalf of the company's long-term investors.
- 04/10/2025
|
If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock
- Over the last week, the capital markets experienced a whirlwind of chaotic selling. Since President Donald Trump announced new tariff policies on April 2, the S&P 500 and Nasdaq Composite each declined about 10% as of this writing.
- 04/10/2025
|
Kenvue: Iconic Brands, but Struggling to Grow
- Explore the exciting world of Kenvue (KVUE -2.53%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
- 04/07/2025
|
OGX® Haircare Introduces Shay Mitchell as First Global Brand Ambassador
- New campaign introduces new Bond Protein Repair hair line designed to deliver effective bonding repair – at a fraction of the price of prestige brands SUMMIT, N.J. , April 7, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE ) announces actress and entrepreneur, Shay Mitchell, as the global brand ambassador for OGX®, stepping in as the face of the brand's Fixer character in their new campaign.
- 04/07/2025
|
Wall Street Says 1970s Stagflation Possible: 4 Safe High-Yield Dividend Kings to Grab Now
- If you were a big fan of “That '70s Show,” get ready because we may soon get a revival, and it will likely not be as entertaining.
- 04/01/2025
|
Best Dividend Aristocrats For April 2025
- Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.
- 03/31/2025
|
Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign
- The Brand's Latest Mineral Sunscreen AddressesTop Consumer Barriers to Daily Sunscreen Use SUMMIT, N.J. , March 31, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) continues to push the boundaries of suncare product development with the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70.
- 03/31/2025
|
Buy 3 'Safer' Dividend Kings Of 25 From March's 55
- The article highlights 55 Dividend Kings, noting that five of the top ten by yield offer annual dividends from a $1K investment exceeding their single share prices. Analysts predict top-ten Kingly net gains ranging from 12.57% to 50.26% for March 2026, with six out of ten top-yield Kings expected to be top gainers. Sixteen out of fifty-five Kings show negative free cash flow margins, making them cash-poor and unsafe to buy; focus on safer Kings like Altria, United Bankshares, and Hormel.
- 03/30/2025
|
Tariffs Could Keep the Federal Reserve on Hold: 5 High-Yield Dividend Kings Are Our Top Calls
- High-yield dividend stocks are a favorite among investors for good reason.
- 03/28/2025
|
2025 Dividend Kings: Strong Run Continues
- The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
- 03/21/2025
|
Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey
- SUMMIT, N.J.--(BUSINESS WIRE)--Today, Kenvue Inc. (NYSE: KVUE) held a ribbon-cutting ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey.
- 03/19/2025
|
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
- Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
- 03/16/2025
|
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
- Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
- 03/14/2025
|
Recession Could Be Coming: 5 Strong Buy High-Yield Dividend Stocks That Will Still Outperform
- The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
- 03/10/2025
|
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.
- 03/07/2025
|
Faber Report: Kenvue settles proxy fight with activist Starboard
- CNBC's David Faber breaks down the latest news on Kenvue.
- 03/05/2025
|
Kenvue settles proxy fight with activist Starboard, appoints three directors
- Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.
- 03/05/2025
|
Kenvue settles proxy fight with activist Starboard
- CNBC's David Faber joins 'Squawk Box' to report on the latest news.
- 03/05/2025
|
Kenvue settles proxy fight with activist Starboard, sources tell CNBC
- Kenvue settles proxy fight with activist Starboard, sources tell CNBC
- 03/05/2025
|
3 Great Value Stocks That Could Crush the S&P 500 This Year
- With the overall market looking expensive, it can be prudent for investors in search of new stocks to add to their portfolios to dig into companies that, for whatever reason, are trading at discounts. Some might have the potential to close their valuation gaps and become above-average investments.
- 03/02/2025
|
3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account
- I'm filling my retirement account with dividend stocks. While I like to see the passive income flow into my portfolio, that's not the main factor.
- 03/01/2025
|
Buy 3 "Safer" Dividend Kings Of 24 Out Of 52 For February
- Seven of the top-ten Dividend Kings by yield offer annual dividends from a $1K investment exceeding their single share prices, making them attractive buys. Six Dividend Kings, including Altria Group and Hormel Foods, are currently fair-priced, with dividends meeting or exceeding their single-share prices. Analysts predict net gains between 15% and 45.53% for the top-ten Dividend Kings by February 2026, based on target prices.
- 02/27/2025
|
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
- Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.
- 02/21/2025
|
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
- Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.
- 02/17/2025
|
Buy 2 February S&P 500 Dividend Aristocrats Out Of 38 'Safer'
- Five of the ten lowest-priced Dividend Aristocrats - Franklin Resources, Realty Income, Amcor, Hormel, and Kenvue - are recommended buys, offering dividends exceeding their single share prices. Analysts project net gains of 15.84% to 46.98% by February 2025 for the Top Ten Aristocrat Dogs, with an average gain of 21.63%. Ten Aristocrats show negative free cash flow margins, making them unsafe buys; Federal Realty, Kenvue, and PepsiCo are among them.
- 02/14/2025
|
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.
- 02/13/2025
|
Kenvue: An Intriguing Turnaround
- Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.
- 02/10/2025
|
Kenvue Is A Mediocre Candidate
- Kenvue, the world's largest pure-play consumer health company, has a market cap of $37.96 billion but struggles with profitability despite decent growth. Management's cost-cutting initiatives show promise, but recent financials reveal mixed results, with revenue slightly up but net income and EBITDA declining. Kenvue's valuation appears relatively cheap compared to peers, yet its fundamentals don't justify a bullish outlook; thus, I rate it a 'hold'.
- 02/08/2025
|
Kenvue, Inc. (KVUE) Q4 2024 Earnings Call Transcript
- Kenvue, Inc. (NYSE:KVUE ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Thibaut Mongon - CEO Paul Ruh - CFO Sofya Tsinis - Head, IR Conference Call Participants Filippo Falorni - Citi Peter Grom - UBS Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Bonnie Herzog - Goldman Sachs Korinne Wolfmeyer - Piper Sandler Nik Modi - RBC Capital Markets Lauren Lieberman - Barclays Steve Powers - Deutsche Bank Operator Hello, and welcome to the Kenvue Fourth Quarter and Full-Year 2024 Earnings Conference Call.
- 02/06/2025
|
Kenvue (KVUE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/06/2025
|
Kenvue's Q4 Sales Miss, Margins Improve
- Consumer healthcare products specialist Kenvue (KVUE -0.34%) reported mixed fourth-quarter and full-year earnings on Thursday, Feb. 6. Adjusted earnings per share (EPS) of $0.26 aligned with the market's consensus expectations.
- 02/06/2025
|
Kenvue (KVUE) Q4 Earnings Meet Estimates
- Kenvue (KVUE) came out with quarterly earnings of $0.26 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.31 per share a year ago.
- 02/06/2025
|
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
- Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and Benadryl.
- 02/06/2025
|
Kenvue Reports Full Year and Fourth Quarter 2024 Results
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. “We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we enter 2025 as a more competitive company with stronger foundations,” said Thibaut Mongon, Chief Executive Officer. “We remain focused on leveraging our increased brand investments to accelerate growth and deliver lon.
- 02/06/2025
|
Kenvue Highlights Commitment to Shareholder Value
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue confirms receipt of Starboard Value submission of nominees to stand for election to the Kenvue Board of Directors from.
- 02/05/2025
|
Neutrogena® Introduces Tate McRae as Global Brand Ambassador
- On the Heels of its 10th Anniversary, the Brand's Iconic Hydro Boost Collection Is Revealing a Juicy, Fresh Take SKILLMAN, N.J. , Feb. 4, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) announces global sensation Tate McRae as the newest face of Neutrogena®.
- 02/04/2025
|
All It Takes Is $3,000 Invested in Each of These 3 Ultra-Reliable Dividend King Stocks to Help Generate Over $300 in Passive Income in 2025
- Dividends can be a great way to generate income from stocks, no matter what the market is doing. But only if the companies paying the dividends are reliable.
- 02/04/2025
|
Gear Up for Kenvue (KVUE) Q4 Earnings: Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Kenvue (KVUE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/03/2025
|
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/30/2025
|
4 Consumer Staple Stocks Likely to Top Earnings Estimates This Season
- Companies with solid brands and efficient cost-management efforts are poised to shine amid a dynamic consumer landscape. KMB, CHD, CLX and KVUE are in focus.
- 01/27/2025
|
Kenvue to Announce Fourth Quarter and Full Year 2024 Results on February 6, 2025
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a repla.
- 01/23/2025
|
These Dividend Stocks Fell Between 1% and 20% in 2024. Here's Why They Are Too Cheap to Ignore and Worth Buying in 2025.
- 2024 was a phenomenal year for broader indexes like the S&P 500 and Nasdaq Composite. But not all stocks joined the party.
- 01/21/2025
|
JPMorgan Analyst Focus List Includes 5 of Our Favorite High-Yield Dividend Giants
- Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
- 01/20/2025
|
4 High-Yield Dividend Kings Baby Boomers Count on for Safe Passive Income
- With the youngest baby boomers (Americans born between 1946 and 1964) approaching retirement age, it's becoming increasingly important to focus on magnificent dividend stocks that will supply significant passive income either in or out of designated retirement accounts like IRAs.
- 01/19/2025
|
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
- Being a long-term investor brings a unique peace of mind. It requires thinking in decades, not months or years, which allows an investor to focus on owning exceptional businesses.
- 01/17/2025
|
Kenvue Declares Quarterly Cash Dividend
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID®.
- 01/16/2025
|
Buy 3 'Safer' Dividend Kings Of 25 From 53 For January
- “A Dividend King [is] a stock with 50 or more consecutive years of dividend increases.”—suredividend.com. 53 Divided Kings, screened as of January 10, 2025, represented all eleven Morningstar Sectors. Broker-estimated top-ten net-gains ranged 22.84%-62.53% topped-by SJW & SCL. By yield, MO topped all the Kings. Top-ten Yields from KVUE, SWK, UBSI, FTS, FRT, BKH, NWN, CDUAF, UVV, & MO, averaged 5.04%.
- 01/15/2025
|
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
- Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/14/2025
|
Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'
- **Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. **Rating Justification:** Six more Aristocrats could meet the ideal dividend-to-price ratio with a 45.4% market downturn, making them fair-priced investment opportunities. **Analyst Projections:** Top-ten Aristocrats are expected to deliver 22% to 33.36% net gains by January 2025, with an average net gain of 24.96%.
- 01/07/2025
|
Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips
- As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.
- 01/03/2025
|
3 Dividend-Paying Value Stocks to Buy Even If There's a Stock Market Sell-Off in 2025
- Investors worried about a stock market sell-off may feel the urge to sell out of their positions and run for the exits. But long-term investors know that it's a mistake to overhaul your investing strategy based on emotion.
- 12/29/2024
|
A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now
- Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading.
- 12/23/2024
|
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
- "A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Sectors. Broker-estimated top-ten net gains ranged from 14.79% to 25.23%, topped by SJW and SWK. By yield, MO topped all the Kings. Top-ten yields from ABBV, ADM, SWK, FRT, FTS, BKH, NWN, CDUAF, UVV, and MO averaged 4.67%.
- 12/13/2024
|
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
- "Dividend Aristocrats
- 12/10/2024
|
Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months.
- Investors often gravitate toward super safe dividend stocks to collect passive income and limit market volatility. But sometimes, even stodgy, boring companies can crush the market.
- 12/04/2024
|
Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
- Kenvue's recent earnings showed improvements, but persistent headwinds, especially in the Skin, Health, & Beauty segment, suggest limited upside potential in the near term. Despite solid dividend growth and cost-cutting initiatives, higher interest rates and economic challenges in China continue to weigh on Kenvue's performance. Management's strategic moves, including increased online presence and partnerships with influencers, aim to combat headwinds and drive future growth.
- 11/27/2024
|
Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mongon, Chief Executive Officer and Paul Ruh, Chief Financial Officer will participate in a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on investors.kenvue.com and a replay will be available on the website followin.
- 11/25/2024
|
Tylenol maker Kenvue hails efficiency gains as activist Starboard watches on
- Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a more intense spotlight coming into these results after reports emerged that activist investor Starboard Value has taken a stake and is eyeing changes.
- 11/07/2024
|
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
- Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bonnie Herzog - Goldman Sachs Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Peter Grom - UBS Filippo Falorni - Citi Steve Powers - Deutsche Bank Keith Devas - Jefferies Nik Modi - RBC Capital Markets Korinne Wolfmeyer - Piper Sandler Jeremy Fialko - HSBC Operator Hello, and welcome to the Kenvue Third Quarter 2024 Earnings Conference Call.
- 11/07/2024
|
Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
- Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/07/2024
|
Kenvue (KVUE) Q3 Earnings Surpass Estimates
- Kenvue (KVUE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
- 11/07/2024
|
Kenvue misses quarterly sales estimates on sluggish skincare sales
- Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from activist hedge fund Starboard Value.
- 11/07/2024
|
Kenvue Reports Third Quarter 2024 Results
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.
- 11/07/2024
|
Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
- 11/04/2024
|
This Big New Development Could Be Bullish for Kenvue Stock
- Can tinkering around the edges actually make this stock more attractive?
- 10/30/2024
|
3 Dividend Stocks to Double Up on Right Now
- While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.
- 10/27/2024
|
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
- Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
- 10/26/2024
|
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
- An activist investor is taking a stake in Kenvue stock.
- 10/26/2024
|
How activist Starboard may help boost value in Kenvue's skin and beauty business
- Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.
- 10/26/2024
|
Is Kenvue Stock a Buy Now?
- The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
- 10/25/2024
|
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
- Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
- 10/22/2024
|
Starboard says Kenvue's skin health segment is weighing on performance
- Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
- 10/22/2024
|
3-Stock Lunch: Kenvue, UPS & Disney
- Sylvia Jablonski, Defiance ETF co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
- 10/21/2024
|
Investor Hoping To "Band-Aid" KVUE Stock Price
- The Wall Street Journal reported that Starboard Value has taken a "sizeable" stake in Kenvue (KVUE) with hopes of matching the company's stock price to competitors. Despite having Tylenol and Band-Aid as part of its brand portfolio, George Tsilis looks at the headwinds facing Kenvue's growth.
- 10/21/2024
|
Kenvue gains on reports activist investor Starboard Value has taken ‘sizeable' stake
- Kenvue Inc (NYSE:KVUE) shares moved more than 6% higher on reports activist investor Starboard Value has taken a stake in the consumer goods company and is eyeing changes. A person familiar with the matter told the Wall Street Journal that Starboard's stake in the Tylenol-maker is “sizeable.
- 10/21/2024
|
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
- Elf Beauty appeared to rally along with KVUE on Monday.
- 10/21/2024
|
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
- Shares of Kenvue (KVUE) took off Monday morning on indications activist investor Starboard Value has taken a large stake in the consumer health products maker.
- 10/21/2024
|
Kenvue shares surge after activist Starboard takes stake
- Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's Jeff Smith is expected to detail the position further at 13D Monitor's Active-Passive Investor Summit on Tuesday.
- 10/21/2024
|
Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.
- Tylenol, Listerine and Band-Aid maker Kenvue has attracted the activist investor, according to a report.
- 10/21/2024
|
Starboard reportedly takes big stake in Tylenol maker Kenvue
- Activist investor Starboard Value has taken a sizeable stake in Kenvue, the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night.
- 10/20/2024
|
Activist investor Starboard Value takes stake in consumer products maker Kenvue, sources say
- Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.
- 10/20/2024
|
Activist Starboard Value Takes Stake in Tylenol-Maker Kenvue
- Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.
- 10/20/2024
|
Kenvue to Announce Third Quarter 2024 Results on November 7, 2024
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) will announce its third quarter 2024 financial results before market open on November 7, 2024.
- 10/18/2024
|
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
- Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/17/2024
|
Kenvue Declares Quarterly Cash Dividend
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock.
- 10/17/2024
|
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
- Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.
- 10/13/2024
|
Buy 7 October Dividend Kings, Watch 10 More
- A Dividend King is a stock with 50 or more consecutive years of dividend increases per suredividend.com. The 53 Dividend Kings, screened as of October 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 13.99%-20.65% topped by Northwest Natural and United Bankshares. By yield, Altria tops all. Top-ten October dogs: HRL, KVUE, FRT, UBSI, FTS, BKH, NWN, CDUAF, UVV, and MO averaged 4.87% in yield.
- 10/11/2024
|
Buy 4 October Dividend Aristocrats & Watch 10
- "Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.
- 10/09/2024
|
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
- Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/02/2024
|
Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business
- Just like trying to catch falling knives, chasing stocks can be a dangerous endeavor. In this update, I share my latest thoughts on Kenvue stock, focusing specifically on the Q2 2024 results that sent the stock soaring 25%. I've incorporated the latest results into my valuation model and explain what the market is currently pricing in for KVUE stock.
- 10/02/2024
|
Kenvue Drives Climate Action Strategy Forward
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) is releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.
- 09/23/2024
|
Buy 7 September Dividend Kings, Watch 9 More
- "What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.” - suredividend.com. The 53 Dividend Kings, screened as of Sept. 10, represented eight of 11 Morningstar Sectors. Broker-targeted top 10 net gains ranged around 11.59%-35.94%, topped by Emerson and Stephan. By yield, Altria tops all. Top 10 September dogs: HRL, KVUE, FRT, FTS, UBSI, BKH, NWN, CDUAF, UVV, and MO averaged 4.70% in yield.
- 09/12/2024
|
Buy 4 September Dividend Aristocrats And Watch 6
- The S&P 500 Dividend Aristocrats list was rebalanced in January 2024, with notable changes including the removal of Walgreens and 3M, and the addition of Fastenal and Kenvue.
- 09/10/2024
|
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
- Kenvue Inc. KVUE — the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol — is showing a bullish pattern on the charts Tuesday.
- 09/10/2024
|
5 Dividend Kings Provide Perfect Passive Income Streams for Retirement
- 24/7 Wall St. Insights Social Security is not enough to provide for a comfortable retirement.
- 09/05/2024
|
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
- Coca-Cola and Pepsi are two proven and reliable dividend stocks. Kenvue's high yield and established portfolio of consumer health brands make it a passive income powerhouse.
- 09/01/2024
|
Kenvue Announces Participation in the Barclays Global Consumer Staples Conference
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be.
- 08/23/2024
|
Passive Income Matters: These 3 Stocks Are Perennial Dividend Growers Worth Buying
- Dividends represent the portion of a company's earnings paid to shareholders, typically on a quarterly basis.
- 08/22/2024
|
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
- Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.
- 08/16/2024
|
Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch
- New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen SKILLMAN, N.J. , Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology.
- 08/15/2024
|
Buy These 5 Dividend Kings in August for Years of Passive Income
- 24/7 Wall St. Insights Passive income is among the best ways to supplement earnings from employment.
- 08/14/2024
|
7 Stable Dividend Stocks to Scoop Up on Discount
- Following the severe market falloff that began last month but accelerated this month, investors may want to consider the inherent comfort of stable dividend stocks. No, these ideas aren't the most glamorous in the world – far from it.
- 08/12/2024
|
Kenvue: Promising Steps Toward Long-Term Success
- Kenvue's share price recently spiked as a result of a strong second quarter earnings report. Kenvue's strong brands continued to gain market shares, showing progress despite challenges in the consumer environment. Strong brand performance with growth in well-known products like Listerine, Tylenol, Zyrtec, and Benadryl.
- 08/11/2024
|
Prediction: These 3 Dividend Stocks Will Pay More in Dividends in 2025
- 24/7 Wall St. Insights The bull market rally that started in the fall of 2023 may be coming to an end.
- 08/08/2024
|
53 August Dividend Kings: Buy 7, Watch 9 More
- “What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.”—suredividend.com. The 53 Dividend Kings, screened as of August 6, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 9.36%-31.67% topped-by PPG, and Target. By yield, Altria tops-all. Top-ten August dogs: NFG, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, & MO averaged 4.92% in yield.
- 08/08/2024
|
Kenvue Goes Boom - Now What?
- Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.
- 08/07/2024
|
The 7 Best Under $20 Stocks to Buy in August 2024
- Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.
- 08/07/2024
|
S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook
- Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.
- 08/06/2024
|
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
- Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
- 08/06/2024
|
Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance
- Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.
- 08/06/2024
|
Kenvue News: Why Investors Are Loving KVUE Stock This Week
- Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.
- 08/06/2024
|
4 Dividend Aristocrats To Buy In August And More To Watch
- “Dividend Aristocrats… in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years.“- Kiplinger.. 67 Aristocrats, screened as of August 2, 2024, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 8.12%-27.1% topped by CVX & TGT.
- 08/06/2024
|
Kenvue Is the S&P 500 Stock After Earnings. Here's Why.
- Shares of the Band-Aid parent are on track for their largest daily percent increase on record.
- 08/06/2024
|
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/06/2024
|
Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates
- Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.
- 08/06/2024
|
Kenvue stock up 9% after earnings beat; consumer health stars
- Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue. The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.
- 08/06/2024
|
Kenvue's stock jumps as Band-Aid, Tylenol parent beat profit and sales expectations
- Shares of Kenvue Inc. KVUE, -3.35% jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing. Net income fell to $58 million, or 3 cents a share, from $430 million, or 23 cents a share, in the year-ago period.
- 08/06/2024
|
Listerine maker Kenvue beats estimates on strong essential health product sales
- Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.
- 08/06/2024
|
Kenvue Reports Second Quarter 2024 Results
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal second quarter ended June 30, 2024.
- 08/06/2024
|
All It Takes Is $10,000 Invested in Coca-Cola and Each of These 2 Dividend Kings to Generate Over $1,000 in Passive Income per Year
- Coca-Cola has turned its business around, and the stock just hit an all-time high. Pepsi's growth is slowing, but the stock remains a great value.
- 08/05/2024
|
Is Kenvue The Next Big Dividend (Growth) Stock?
- Kenvue stock has not participated in the recent rotation into value stocks. It trades at a forward P/E of 16 and a free cash flow yield of 6%. Such a valuation is indeed rare to find in the - typically overvalued - consumer staples sector, as is a starting dividend yield of 4.4%. In this article, I explain the main reasons for my growing enthusiasm and why I expect to initiate a long position in KVUE stock shortly.
- 08/03/2024
|
Kenvue Announces Board Changes with Two New Independent Directors
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announces the implementation of a Board of Directors succession process.
- 07/31/2024
|
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
- Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2024
|
4 Top Dividend Stocks Yielding Over 4% to Buy Hand Over Fist Right Now for Decades of Passive Income
- Yields are higher right now, thanks to higher interest rates. With the Fed poised to cut rates, these higher yields might not last much longer.
- 07/28/2024
|
5 High-Yield Dividend Aristocrats Offer Investors a Passive Income Grand Slam
- 24/7 Insights The Dividend Aristocrats offer some of the very passive income solutions.
- 07/26/2024
|
3 Dividend Stocks to Buy at a 52-Week Low
- In recent trading days, investors have been rotating from growth stocks to value stocks, creating a fertile ground for overlooked dividend stocks. With the spotlight having shone brightly on growth stocks during last year's rally, many dividend stocks have been left in the shadows.
- 07/22/2024
|
5 Overlooked Dividend Kings to Buy Hand-Over-Fist Now
- 24/7 Insights The Dividend Kings provide dependable passive income streams.
- 07/22/2024
|
7 Consumer Staples Stocks to Buy at a 52-Week Low in July
- For the last two years, investors in consumer staples stocks saw every tiny step forward smacked down by two large steps back. Therefore, the 900+-point gain in the Dow Jones Industrial Average (DJIA) the week of July 15 was noteworthy.
- 07/19/2024
|
Readers Identify 30 Ideal June Dividend Buys Out Of 40 Nods
- Prior to June 30, 2024, my REaders mentioned 40 equities in their comments on my articles. Some bad news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: VZ, EPD, ECC, OXLC, NEP, TTE, RC, KVUE, ORC, and TPVG averaged 21.11% net gains from reader data collected 7/12/24. Ten analyst-target-augured June TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: NEP, RC, O, ORC PFE, VZ, EPD, TPVG, TTE, and KVUE, boasting a 12.02% average target price upside estimate.
- 07/17/2024
|
6 Dividend Kings to Buy in July That Deliver Huge Passive Income
- 24/7 Insights The Dividend Kings have all raised their dividend for at least 50 years.
- 07/15/2024
|
53 July Dividend Kings: Buy 8, Watch 8 More
- "What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.
- 07/10/2024
|
4 Dividend Aristocrats To Buy In July And 4 To Watch
- "Dividend Aristocrats
- 07/09/2024
|
3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July
- Kenvue is less than 3% off its 52-week low, but the sell-off is a buying opportunity. Shares of dividend powerhouse American Electric Power are on a summer sale.
- 07/04/2024
|
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
- Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more.
- 07/02/2024
|
7 S&P 500 Stocks to Buy on the Dip: June 2024
- Is the market set to continue heading higher? Or after a tremendous run, are the bulls finally running out of steam?
- 06/26/2024
|
Kenvue Releases Inaugural Healthy Lives Mission Report
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue shares progress on its Environmental, Social and Governance goals in its first-ever Healthy Lives Mission Report.
- 06/25/2024
|
Focused On Income? 3 Deep Value Stocks To Add To Your Portfolio
- Dividend investing is an attractive strategy for consistent income. And could reward investors with multiple dividend checks over a month span if structured properly. As a retiree who gets paid once on a monthly basis, dividend investing has allowed me to structure my payments, helping grow my dividend snowball at a faster pace. Verizon, Kenvue, and Cisco Systems offer well-covered dividends and potential upside for income-focused investors with a longer-term investment horizon.
- 06/23/2024
|
Two High Conviction Dividend Buys For This Upside-Down Market
- FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.
- 06/22/2024
|
3 Healthcare Stocks to Buy Now: June 2024
- Healthcare stocks offer a haven for investors amidst the uncertainty. The Fed elected to hold interest rates at a 23-year high between 5.25% and 5.5% to combat persistent inflation.
- 06/20/2024
|
5 Dividend Kings to Buy Now for Dependable Retirement Passive Income
- While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.
- 06/19/2024
|
2 Undervalued Dividend Stocks the Best Managers Are Buying
- #Morningstar #DividendStocks #StockInvesting Some top concentrated fund managers bought these cheap dividend stocks trading at big discounts. 00:00 Introduction 00:14 Realty Income O 01:08 Kenvue KVUE Susan Dziubinski: I'm Susan Dziubinski with Morningstar.
- 06/18/2024
|
6 of Wall Street's Favorite High-Yield Blue Chip Dividend Stocks to Buy in June
- 24/7 Insights Quality dividend stocks can generate solid total returns and yield passive income.
- 06/17/2024
|
5 Dividend Aristocrats Will Deliver Steady Passive Income During a Volatile Summer
- 24/7 Insights Passive income is an easy way to supplement retirement and pension distributions.
- 06/15/2024
|
The 7 Best Under $20 Stocks to Buy in June 2024
- The May inflation readings showed cooling consumer and producer prices. However, in 2024, it's important to define the meaning of words.
- 06/15/2024
|
Kenvue: Portfolio Of Products Can Be Replaced With Generic Brands
- Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.
- 06/12/2024
|
3 Dividend Aristocrats to Buy Today
- 24/7 Insights: Investors looking for dividend safety love the Dividend Aristocrats The Dividend Aristocrats are the perfect vehicle to deliver passive income Access 2 legendary, high-yield dividend stocks Wall Street loves Investors love dividend stocks because they provide dependable income and a great opportunity for solid total return.
- 06/10/2024
|
4 Dividend Aristocrats To Buy In June And 4 To Watch
- "Dividend Aristocrats... in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing.
- 06/07/2024
|
Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue will participate in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France.
- 05/24/2024
|
3 Healthcare Stocks to Buy Now: May 2024
- It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions.
- 05/21/2024
|
Divide and Conquer: 3 Stock Spinoffs Set to Trounce the Market
- Too often spinoff stocks don't perform well out of the gate. Because an investor bought the business of the parent company, he doesn't care too much about whatever side project is being shed.
- 05/16/2024
|
Kenvue Announces Pricing of Secondary Offering
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of its common stock.
- 05/14/2024
|
Johnson & Johnson Is Officially Getting Out of Kenvue (KVUE) Stock
- Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.
- 05/13/2024
|
Kenvue's stock falls after company announces 182.3 million secondary stock offering
- Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.
- 05/13/2024
|
Kenvue Announces Launch of Secondary Offering
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.
- 05/13/2024
|
4 Strong Buy Dividend Aristocrats Wall Street Loves Are Trading Just Above 52-Week Lows
- Want retirement to come a few years earlier than you'd planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
- 05/09/2024
|
4 Dividend Aristocrats To Buy In May Plus 4 To Watch
- "Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.
- 05/08/2024
|
Kenvue shares rise on first quarter earnings beat
- Kenvue Inc (NYSE:KVUE) shares moved higher after the Tylenol-maker posted better-than-expected first quarter earnings on Tuesday. Shares of the Johnson & Johnson (NYSE:JNJ) consumer healthcare spin-off company - whose brands also include Neutrogena, Listerine, Band-Aid, and Aveeno – added 5.1% at $19.84 late morning.
- 05/07/2024
|
Kenvue's stock jumps 4.7% after earnings beat and news company to cut 4% of global workforce
- Kenvue Inc.'s stock KVUE, -0.63% jumped 4.7% early Tuesday, after the consumer health business that was spun out of Johnson & Johnson last year posted better-than-expected first-quarter earnings and announced plans to cut jobs. The company had net income of $296 million, or 15 cents a share, for the quarter, down rom $469 million, or 27 cents a share, in the year-earlier period.
- 05/07/2024
|
Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs
- Kenvue beat Wall Street estimates for first-quarter profit on Tuesday, and said it would cut 4% of its global workforce amid the Tylenol and Band-Aid maker's efforts to expand its key brands.
- 05/07/2024
|
Kenvue Reports First Quarter 2024 Results
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024. “We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest more behind our brands, and to foster a culture that rewards performance and impact,” said Thibaut Mongon, Chief Executive Officer. “We began executing against these priorities during the quarter, enabling a solid start to the year.
- 05/07/2024
|
Investor Alert: Are These 3 Spinoff Stocks Destined to Sizzle or Fizzle?
- There's a lot of evidence suggesting that spinoff stocks are generally a good idea to watch. Following a split from their parent company, many such firms do well thanks to their efficiency and newly-found flexibility.
- 05/06/2024
|
7 Dividend Aristocrats Paying Sky-High Yields: April 2024
- Few investment strategies have performed as well for as long as dividend investing. Numerous studies show that buying stocks that have initiated a dividend and then increased it over time beat all other stocks on the market.
- 04/30/2024
|
7 Stocks to Buy if Inflation Continues to Reign in 2024
- Before considering which stocks to buy if inflation continues, it's good to remember the relationship between inflation and interest rates. The latest reading on CPI and PPI shows that the declining inflation rate may be ramping back up.
- 04/27/2024
|
Steady Eddies: 7 Rock-Solid Stocks to Anchor Your Portfolio in April
- Perhaps the biggest justification for steady stocks comes from an asset class completely unrelated to the equities market: cryptocurrencies. After the benchmark blockchain asset hit a record high earlier this year, the sector has struggled for traction.
- 04/26/2024
|
Here Are My Top 5 Dividend Kings to Buy Right Now
- Dividend income can be a good way to bolster growth in your portfolio's value. Dividend Kings are companies that have paid and raised their dividend for at least 50 years.
- 04/25/2024
|
Kenvue Declares Quarterly Cash Dividend
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue today announced a dividend payable in Q2 of $0.20 per share on the Company's common stock. The dividend is payable on May 22, 2024.
- 04/25/2024
|
3 Dividend Kings Down 11% You'll Regret Not Buying on the Dip
- Dividend stocks have a proven record of stock market outperformance. For nearly 100 years, income-generating stocks on the S&P 500 have beaten non-payers.
- 04/22/2024
|
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
- An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue involving talc products.
- 04/20/2024
|
Invest Like a Hawk: 7 Stocks to Own If the Fed Stays Tough
- While earlier discussions focused on the Federal Reserve's potential interest rate cuts, that's no longer a surefire proposition, thus warranting consideration for stocks for Fed hikes. Let's break this matter down.
- 04/17/2024
|
6 Dividend Aristocrats to Buy for Reliable Passive Income
- Its products are sold under these brands: Exxon Esso Mobil The Chemical Products segment manufactures and markets petrochemicals, including olefins, polyolefins, and intermediates.
- 04/16/2024
|
55 April Dividend Kings: Buy 8, Watch 8
- "What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 55 Dividend Kings screened as of April 10 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 15.19%-33.38% topped-by Middlesex Water, and SJW Group. By yield, Leggett tops-all. Top-ten April Kings: FRT, UBSI, FTS, BKH, NWN, CDUAF, MMM, UVV, MO, & LEG averaged 6.24% in yield.
- 04/12/2024
|
Why Kenvue (KVUE) Could Beat Earnings Estimates Again
- Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/10/2024
|
Here's why Harris' Alex Fitch favors Kenvue
- Alex Fitch, Harris Associates director of U.S. Research, joins 'Money Movers' to discuss Fitch's investment thesis towards Delta Air Lines, whether investors are not supposed to buy cyclical stocks at peak earnings, and more.
- 04/10/2024
|
Kenvue Layoffs 2024: What to Know About the Latest Neutrogena Job Cuts
- Kenvue (NYSE: KVUE ) has announced plans to lay off over 100 employees at one of its leading brands. Specifically, the prominent skincare, cosmetics and health company will be implementing job cuts at Neutrogena, a well-known name in the health and beauty space.
- 04/09/2024
|
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 04/09/2024
|
Kenvue to Announce First Quarter 2024 Results on May 7, 2024
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue, the world's largest pure-play consumer health company by revenue, will announce its 2024 Q1 results before market open on May 7, 2024.
- 04/05/2024
|
Stock Market Looking Dangerous – 6 Safe Large Cap Dividend Blue Chips
- ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored) If you want to retire before 65, pay attention.
- 03/25/2024
|
7 Defensive Stocks to Build a Moat Around Your Portfolio
- While the idea of defensive stocks might not seem so relevant amid blistering market performances, investors ought to consider looking under the hood. According to Bank of America, investors have drained $4.4 billion from technology-based securities.
- 03/19/2024
|
7 High-Quality Blue-Chip Stocks to Buy if You're Looking for Stability
- At first glance, a concerted focus on stable blue-chip stocks might seem excessively cautious. After all, the market is booming, companies are hiring and people are spending.
- 03/12/2024
|
Looking To Start Earning Passive Income in March? Here Are 6 Top Dividend Stocks
- Are you ready for retirement? Planning for retirement can be overwhelming, that's why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
- 03/11/2024
|
5 Dividend Aristocrats Signal Buy In March With 6 To Watch
- "Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 67 Aristocrats, screened as of March 6, 2024, represented all eleven Morningstar Sectors. Broker estimated-top ten net gains ranged 15.93%-27.67% topped by NEE & ADM.
- 03/11/2024
|
David Einhorn's Greenlight Capital adds Kenvue, ETFs and exits Southwestern Energy
- David Einhorn's hedge fund Greenlight Capital picked up a new stake in Kenvue Inc. KVUE — formerly the consumer healthcare division of Johnson & Johnson JNJ — in the fourth quarter, according to a public filing Wednesday.
- 02/14/2024
|
February's 55 Dividend Kings: Buy 9, Watch 3
- "What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.”—suredividend.com. The 55 Dividend Kings screened as of February 12 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 14.3%-28.7% topped-by Northwest Natural, and Archer-Daniels Midland. By yield, Altria tops-all. Top-ten February King yields reported for UBSI, FRT, FTS, BKH, NWN, CDUAF, UVV, MMM, LEG, & MO averaged 6.00%.
- 02/14/2024
|
Kenvue: This Dividend Newcomer Is Worth A Look
- Kenvue, a spin-off from Johnson & Johnson, has solid financials and a strong portfolio of iconic consumer products. The company's dividend is safe with a conservative payout ratio, and they initiated a share repurchase program during Q3. Because of this, I've initiated the stock as a speculative buy currently. Kenvue has a strong balance sheet and a lower valuation compared to other consumer staple stocks, making it an attractive investment opportunity.
- 02/13/2024
|
Kenvue shares hit as profit forecast below expectations
- Band-Aid maker Kenvue Inc (NYSE:KVUE) saw its shares hit on Thursday morning after laying out guidance below Wall Street expectations. Kenvue said adjusted profit would sit between US$1.10 to US$1.20 per share for the year ahead in Thursday's fourth quarter results, lower than analysts' estimates of US$1.26.
- 02/08/2024
|
J&J spinoff Kenvue stock loses ground as profit drops
- Kenvue Inc.'s stock KVUE, -0.39% fell by 3.2% in premarket trading on Thursday after the household products spin-off of Johnson & Johnson JNJ, -0.05% reported lower fourth-quarter profit and said its 2024 earnings would fall short of the FactSet consensus estimate. It also missed its revenue target for the fourth quarter.
- 02/08/2024
|
Tylenol maker Kenvue forecasts annual profit below estimates after weak quarter
- Kenvue forecast full-year profit below analysts' expectations after missing quarterly sales estimates on Thursday, as the Tylenol maker faces sluggish demand in China and slowing growth for skin and beauty products in the U.S. The company, spun off from Johnson & Johnson in August, missed Street estimates for fourth-quarter sales in both its self-care, as well as skin health and beauty segments.
- 02/08/2024
|
5 Dividend Aristocrats Signal Buy In February And 6 To Watch
- "Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 11.95%-40.69% topped-by APD & ADM.
- 02/07/2024
|
7 Dividend Stocks Worth Holding for the Long Haul
- Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as artificial intelligence emerged.
- 02/06/2024
|
3 Top Value Stocks to Buy and Hold for 2024
- These high-quality companies are solid—and their stocks look cheap.
- 01/30/2024
|
Hedge Fund Favorites: 7 Stocks the Big Money Is Loving Now
- Ever had the experience of befriending the schoolyard bully? That's sort of the underlying catalyst behind hedge fund favorite stocks.
- 01/29/2024
|
3 personal care stocks that smell like good earnings plays
- 2023 was a year to forget for the personal care industry. With traders clamoring for growth-oriented technology and media shares, the defensive group became an afterthought and woefully underperformed the broad U.S. equity market.
- 01/23/2024
|
I'm Putting My Cash Stockpile to Work on These 3 Stocks
- Chevron can grow its cash flow at a strong rate even if oil prices cool off. Kenvue is in an excellent position to grow shareholder value as an independent company.
- 01/21/2024
|
3 Dividend Stocks for January 2024
- The dividend prospects of three firms with wide or narrow Morningstar Economic Moat Ratings.
- 01/20/2024
|
Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson is warranted, especially in light of the split-off of its Consumer Health segment (Kenvue stock) and amid the ongoing talc litigation. I share my view on JNJ's two remaining segments, their future prospects, and the decline in cash flow due to the split-off of the Consumer Health segment.
- 01/16/2024
|
Hidden High-Yielders: 7 Overlooked Stocks with Attractive Dividends
- If you're a growth investor, an article about overlooked high-yield dividend stocks is not for you. However, with the recent numbers showing that inflation is that dinner party guest that is overstaying its welcome, you may not want to dismiss income-generating stocks too quickly.
- 01/14/2024
|
3 Super-Safe High-Yield Dividend Stocks You Can Buy Right Now
- Brookfield Infrastructure's underlying businesses make its distributions highly dependable. Enterprise Products Partners has increased its distribution for 25 consecutive years and counting.
- 01/14/2024
|
3 Unshakeable Dividend Stocks for Lifelong Wealth
- While many, if not most investors, appear bullish about the market's prospects this year, it's never a bad time to consider long-term dividend stocks. By that, we're talking about profitable, relevant enterprises that you can trust.
- 01/10/2024
|
7 Stable Stocks to Buy No Matter What Happens to Interest Rates
- While avoiding a recession last year boosted sentiment for 2024, concerned investors may still want to consider stable stocks. You just don't know what might happen next.
- 01/10/2024
|
U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map
- Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).
- 01/10/2024
|
U.S. IPO Weekly Recap: 2024 IPO Market Starts Off With $2B Additions To The Pipeline
- While the calendar was quiet this past week, six IPOs joined the pipeline, two of which we estimate could raise $1 billion or more. Three biotechs filed to raise $100 million.
- 01/06/2024
|
Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce financial results for the fourth quarter and full year ending December 31, 2023, on February 8, 2024.
- 01/05/2024
|
Still Worried About a 2024 Recession? 7 Stocks to Watch.
- One of the main themes of 2023 may be relief – that is, relief that we avoided a downcycle – and so it begs the question: why talk about 2024 recession worries? More to the point, why deal with recession stocks?
- 01/04/2024
|
January's 54 Dividend Kings: Buy 8, Watch 5
- "There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 54 Dividend Kings screened as of December 29 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 18.52%-38.49% topped-by Northwest Natural, and Altria Group. By yield, Altria tops-all. Top-ten Kingly January yields reported for ABBV, FTS, FRT, BKH, UVV, NWN, MMM, CDUAF, LEG, & MO averaged 5.45%.
- 12/31/2023
|
3 Top Dividend Stocks I Can't Wait to Buy in 2024
- Clearway Energy has the power to deliver high-end dividend growth in 2024. Kenvue should deliver the first of many dividend increases in the coming year.
- 12/29/2023
|
Forever Favorites: 7 Dividend Stocks to Buy and Never Sell
- Some investments just look after themselves. They are “set it and forget it” kind of stocks.
- 12/19/2023
|
Kenvue Shares Are Rising. Tylenol Litigation Fades Into the Rearview.
- A ruling hurts litigation against Kenvue that alleges a link between prenatal exposure to the company's Tylenol and autism spectrum disorder or ADHD.
- 12/19/2023
|
Kenvue shares rise after favorable court ruling in Tylenol litigation
- Shares of Tylenol maker Kenvue Inc. KVUE, +0.10% gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs' expert testimony will be blocked in a case involving product-liability claims against the manufacturers of Tylenol and generic acetaminophen. Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants' motion to exclude plaintiffs' expert opinions on whether in-utero exposure to acetaminophen could cause children to develop autism spectrum disorder and attention deficit hyperactivity disorder.
- 12/19/2023
|
Naval Task Force; Japanese Takeover
- Naval Task Force; Japanese Takeover
- 12/19/2023
|
Kenvue: A High-Quality Consumer Health Company on Sale
- In May, Kenvue Inc. (KVUE, Financial) successfully concluded its separation from Johnson & Johnson (JNJ, Financial); however, its stock has experienced a decline about 25% since the completion of this process, likely driven by Investors nervousness about Tylenol litigation. The drop in value appears to be excessive even if the company may have to settle some lawsuits.
- 12/12/2023
|
Life-Changing Investments: 3 Stocks That Will Set You Up for the Long Haul
- The last four years on Wall Street gave investors whiplash. A decade-long bull market came to a screeching halt as the global pandemic brought on one of the worst market crashes in recent memory.
- 12/11/2023
|
3 Dividend Stocks Worthy Of A Buy In December 2023
- November was the best month for the S&P 500 since July 2022, breaking a three-month losing streak. The stock market appears overvalued after the strong November performance, suggesting a minor pullback may be needed. 3 undervalued dividend stocks to consider buying in December are Kenvue, 3M, and VICI Properties.
- 12/04/2023
|
Fresh on the Market: 3 Top Picks From the Renaissance IPO ETF
- The initial public offering (IPO) market has not done well in 2023. The most recent deals have faltered, falling below their IPO pricing on day one or soon after.
- 11/30/2023
|
2023's most anticipated IPOs weren't always the big winners
- So far in 2023, 146 companies have gone public in the U.S. markets, down 16.09% from the same time last year. Although the IPO market has been choppy amid higher interest rates and broad equity market uncertainty, the new companies as a whole have outperformed the S&P 500.
- 11/29/2023
|
Kenvue: Dude, Where's My Dividend Growth?
- Dividend stocks became unattractive due to weak equities and high Treasury rates, but some are starting to look more attractive again. Kenvue, a spin-off from Johnson & Johnson, lacks growth potential and has stagnant margins and revenue growth. Kenvue's high debt and limited free cash flow make it unlikely to sustain dividend growth, and its valuation is unattractive compared to J&J.
- 11/26/2023
|
Top 5 Stocks The Smart Money Is Buying
- Hedge funds are managed by professional fund managers and consist of pooled investment funds from various investors. Hedge funds must file a 13-F with the SEC, which shows their buys and sells for the quarter. Here are the top 5 most purchased individual stocks by hedge funds during the most recent quarter.
- 11/21/2023
|
7 Safe Stocks to Buy if You Think Q3's Gangbuster Growth Won't Last
- At first glance, the proposal to dive into safe stocks to buy might appear overly conservative. As NPR recently pointed out, the U.S. GDP grew 4.9% in the third quarter, catalyzed by stronger-than-expected consumer spending.
- 11/09/2023
|
U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
- Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was up 14.0%. Renaissance Capital's IPO ETF tracks Renaissance IPO Index, and top ETF holdings include Palantir Technologies and Kenvue.
- 11/04/2023
|
The 3 Best Forever Stocks to Buy in November
- Anytime you bring up the concept of “forever stocks,” you're running the risk of incurring a serious tail risk. Obviously, forever is a long time – long enough for something to go wrong.
- 11/03/2023
|
Can Kenvue Be a Reliable Dividend Stock to Hold for the Long Haul?
- Kenvue stock pays a fairly high dividend that yields 4.4%. The company is expecting modest revenue growth of around 6% this year.
- 11/01/2023
|
Kenvue Inc. (KVUE) Q3 2023 Earnings Call Transcript
- Kenvue Inc (NYSE:KVUE ) Q3 2023 Earnings Conference Call October 26, 2023 8:30 AM ET Company Participants Tina Romani - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director Paul Ruh - Chief Financial Officer Conference Call Participants Andrea Teixeira - JPMorgan Chase and Company Steve Powers - Deutsche Bank Jason English - Guggenheim Partners Anna Lizzul - Bank of America Merrill Lynch Filippo Falorni - Citi Susan Anderson - Canaccord Genuity Operator Greetings, and welcome to Kenvue's Third Quarter 2023 Earnings Conference Call. My name is Darryl, and I'll be your operator today.
- 10/28/2023
|
Sanofi to create its own Haleon, Kenvue as its stock price tumbles
- Sanofi (FRA: SNW), the giant healthcare company, is considering spinning off its consumer health business. In a statement, the management said it was hoping to create a separate company listed in France.
- 10/27/2023
|
Kenvue CEO Thibaut Mongon: We feel very good about the strength of our business model
- Kenvue CEO Thibaut Mongon joins ‘Squawk on the Street' to discuss the company's latest quarter, their new products in the market, and more.
- 10/26/2023
|
Kenvue shares lower amid slow start to cold and flu season
- Kenvue Inc's shares fell 1.7% in pre-market trading after the company posted in-line third-quarter earnings but tightened its full-year guidance after a slow start to the flu and cold season. The company, the former consumer health operations of Johnson & Johnson (NYSE:JNJ) posted net income of $438 million, or 23 cents a share, for the quarter, down from $586 million, or 34 cents a share, a year ago.
- 10/26/2023
|
Kenvue's stock slides premarket as company reports slow start to flu and cold season
- Kenvue Inc.'s stock KVUE, -1.25% fell 2.4% in premarket trade Thursday, after the company posted in-line third-quarter earnings but tightened its full-year guidance after a slow start to the flu and cold season. The company, the former consumer health operations of Johnson & Johnson JNJ, +0.22%, posted net income of $438 million, or 23 cents a share, for the quarter, down from $586 million, or 34 cents a share, in the year-earlier period.
- 10/26/2023
|
Kenvue reports higher Q3 revenue on self-care products strength
- Kenvue on Thursday reported higher third-quarter revenue, owing to strong demand for its self-care and skincare products such as Tylenol and Neutrogena.
- 10/26/2023
|
Kenvue is one of few IPOs trading cheap relative to long-term value: Lido Advisors' Gina Sanchez
- Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss IPOs performing below their debut prices, defensive IPO names to buy, and what names consumers will be willing to pay for in a slowing environment.
- 10/20/2023
|
Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond
- Kenvue Inc., a subsidiary of Johnson & Johnson, is a major player in the consumer health industry with a diverse range of products. The company successfully completed its IPO, generating net proceeds of approximately $4.2 billion. Kenvue faces competition from industry leaders and spinoff companies, but its strong brand portfolio and global presence give it a competitive advantage.
- 10/19/2023
|
An IPO Pro Buys More Palantir, Rivian, and Kenvue. It Sold Li Auto.
- Renaissance Capital LLC's passive IPO-focused ETFs loaded up on Palantir, Rivian, and Kenvue stock, and exited an investment in Li Auto in the third quarter.
- 10/15/2023
|
Johnson & Johnson's 3Q earnings in spotlight next week following Kenvue split
- Johnson & Johnson (NYSE:JNJ) is slated to report earnings before the market opens on Tuesday in what will be the company's first report since spinning off its consumer health division, Kenvue. For its third quarter, JNJ is expected to post revenue of $21.04 billion and earnings of $2.51 per share, compared to revenue of $23.79 billion and earnings of $1.68 per share a year earlier.
- 10/13/2023
|
7 High-Growth S&P 500 Stocks to Buy Now
- While publicly traded securities that benefit from significant upside potential usually carry a higher-risk profile, with high-growth S&P 500 stocks, you can almost get the best of both worlds. To be fair, we need to set some expectations.
- 10/12/2023
|
IPOs are out of fashion. Here's what companies are doing instead.
- While the current deal landscape on Wall Street remains low on M&A, initial public offerings (IPOs), and other transactions, corporate spinoffs are chugging along.
- 10/06/2023
|
2 Magnificent Dividend Kings to Buy Now
- Coca-Cola and J&J both have long track records of increasing dividend payments to shareholders. These companies also offer bright earnings prospects well into the future, thanks to their solid products.
- 10/05/2023
|
Here's Why Kenvue Stock Is (Slightly) Riskier Than It Seems
- Kenvue is a fairly safe stock, thanks to its consistent sales of critical goods. However, it doesn't have many opportunities to expand more rapidly than it is now.
- 10/04/2023
|
Could Kenvue Follow in the Footsteps of Johnson & Johnson and Become a Top Dividend Stock?
- J&J recently spun off its billion-dollar consumer health business to form Kenvue. Kenvue announced a dividend during its first earnings report as an independent entity.
- 10/01/2023
|
Is Kenvue Stock Too Pricey to Buy?
- Kenvue's shares are pricey because it's expected to be a safe bet for investors. Its growth rate is relatively low for its valuation, at least so far.
- 09/30/2023
|
3 Best Stocks to Buy in September and Hold Forever
- Kenvue is poised to make its mark as a great business with a new name. Abbott Labs has long-term upside in key healthcare end markets.
- 09/24/2023
|
Kenvue to Announce Third Quarter 2023 Results on October 26, 2023
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023.
- 09/22/2023
|
Here are the 14 stocks Jim Cramer is watching, including Apple, Goldman Sachs, Amazon
- Here are some of the tickers on my radar for Wednesday, Sept. 20, taken directly from my reporter's notebook.
- 09/20/2023
|
2 Incredibly Cheap Dividend Stocks to Buy Now
- High-quality dividend stocks tend to trade at enormous premiums. AT&T and Kenvue both trade at attractive multiples.
- 09/20/2023
|
Kenvue Is Not The Better Johnson & Johnson, Also Not For Dividend Investors
- Kenvue faces significant challenges in the consumer healthcare sector, including sluggish growth, intense competition, and middle-tier brand positions. While the company has manageable debt levels, its margins aren't high. The valuation of Kenvue is average, which might still warrant caution given some of its risks. Kenvue's non-cyclical business model offers stability, potentially making it an attractive option for dividend investors.
- 09/19/2023
|
Kenvue: Interesting Times
- Kenvue's shares have fallen since its IPO due to high valuations and concerns about its growth composition. The company, a spin-off from Johnson & Johnson, is well-diversified with leading brands in consumer health products. Despite flattish revenue, Kenvue has seen strong growth in the second quarter, but it is driven by pricing rather than volumes.
- 09/18/2023
|
Johnson & Johnson: Kenvue Spin-Off Unlikely To Drive Market-Beating Returns
- Johnson & Johnson had spun off Kenvue, its consumer health division, to boost growth in its more profitable pharmaceutical and medical technology sectors. JNJ achieved a steady 3.3% revenue growth over the past decade with a stable 26.6% average operating margin, showing resilience even during market turbulence. While analysts predict an annualized EPS growth of 4%, I hold a more optimistic view, expecting JNJ to achieve approximately 5% EPS growth over the next decade.
- 09/18/2023
|
3 High-Quality Dividend Stocks Yielding 3%-Plus to Buy for Decades of Rising Income
- American Tower has increased its payout every year since becoming a REIT. Brookfield Renewable has boosted its dividend by at least 5% annually over the past 12 years.
- 09/17/2023
|
3 Great Dividend Stocks You Can Buy for Less Than $50
- Kroger's reasonable valuation offers much more upside than your traditional grocer. Rollins' top-notch profitability highlights its incredible track record of tuck-in acquisitions.
- 09/15/2023
|
Better Buy: J&J vs. Kenvue
- Johnson & Johnson recently spun off its consumer health unit into a new company called Kenvue. The consumer health segment weighed on J&J's growth, but it could progress successfully as an independent business.
- 09/13/2023
|
Kenvue oversold, concerns priced in, says Deutsche
- Kenvue Inc shares rose 2.5% in pre-market trading on Monday boosted by an upgrade by Deutsche Bank. The German investment bank has moved the firm, the consumer-health business spun-out of Johnson & Johnson (NYSE:JNJ), to buy from hold with an unchanged price target of $27.
- 09/11/2023
|
J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block
- You're familiar with its products, including Tylenol, Neutrogena, Listerine and Johnson's Baby Shampoo. Still, you may not be up to speed on Kenvue Inc. NYSE: KVUE and its status as a long-term dividend payer.
- 09/07/2023
|
1 Brand-New Dividend Stock Income Investors Won't Want to Miss
- Kenvue, which was recently spun off from Johnson & Johnson, already pays an attractive dividend. The company supports that payout with a strong financial profile and durable business.
- 09/07/2023
|
Is J&J a Buy After the Kenvue Separation?
- J&J recently completed the spinoff of its consumer health business, letting go of star products that populate most of our medicine cabinets. But J&J's two other units, pharmaceuticals and medtech, actually have driven more growth for the company in recent times.
- 09/06/2023
|
Kenvue: Charting A Healthy Future In Consumer Health
- Kenvue Incorporated is a leader in the consumer health industry with a large catalog of notable consumer brands. Kenvue has high brand recognition and market share in various sub-sectors of the health industry. Despite initial struggles with costs after the spinoff from Johnson & Johnson, Kenvue is projected to have long-term growth and is a promising stock for investment.
- 09/06/2023
|
Is This Incredible Dividend Stock Still a Buy Following Its Recent Split?
- Johnson & Johnson refreshed its financial guidance following its split from Kenvue. The healthcare behemoth offset most of the financial impact of the split because the exchange offer lowered its share count.
- 09/02/2023
|
Johnson & Johnson Forecasts Double-Digit Earnings Growth After Kenvue Spin-Off
- Johnson & Johnson (JNJ) on Wednesday released its first earnings forecast as a standalone pharmaceutical and medical devices company, estimating double-digit growth in earnings this year.
- 08/30/2023
|
Johnson & Johnson sets out new guidance after Kenvue split
- Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue. J&J, which is now focused on its pharmaceutical and medical-technology businesses, said second-quarter sales were $21.52 billion, up 6.5% from a year ago.
- 08/30/2023
|
Johnson & Johnson Maintains Dividend After Kenvue Spinout
- Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and sales projections.
- 08/30/2023
|
J&J revises 2023 sales, profit outlook lower after Kenvue separation, will maintain dividend
- Johnson & Johnson JNJ, +0.01% updated on Wednesday its 2023 financial guidance in the wake of the Kenvue Inc. KVUE, -0.48% separation that was completed last week. The drug maker now expects full-year reported sales of $83.2 billion to $84.0 billion, down from previous guidance of $98.8 billion to $99.8 billion.
- 08/30/2023
|
Options Bulls Pick Up on Blue-Chip's Split-Off
- Dow member Johnson & Johnson (JNJ) last week completed a split-off exchange offer of 1.53 billion shares of Kenvue Inc (NYSE:KVUE) worth roughly $40 billion.
- 08/28/2023
|
J&J's Kenvue Exchange Offer Was a Big Win for the Little Guy
- Small investors earned a nice payday of more than $1,000 if they tendered 99 shares of stock in the swap, which expired last week.
- 08/25/2023
|
Johnson & Johnson: Kenvue Separation Won't Impact Dividends
- Johnson & Johnson recently completed the Kenvue spinoff. We outline the impacts on its dividend payouts from this spinoff. I analyzed its dividend payout both using simple payout ratios and also using a more holistic approach such as the dividend cushion ratio.
- 08/24/2023
|
Here are 16 stocks Jim Cramer is watching, including J&J split-off Kenvue, Petco, GM
- Here are some of the tickers on my radar for Thursday, Aug. 24, taken directly from my reporter's notebook.
- 08/24/2023
|
Kenvue completes separation from J&J ahead of S&P 500 inclusion
- Kenvue announced that Wednesday, August 23, marked its first day as a fully independent company after it completed its separation from Johnson & Johnson (NYSE:JNJ). The consumer health company, whose brands include Aveeno, Band-Aid, Listerine, Neutrogena, and Tylenol, was spun off from J&J earlier this year, debuting on the New York Stock Exchange on May 4 for $22 a share.
- 08/23/2023
|
J&J Makes it Official: Kenvue Stock Swap Offer Was a Huge Hit With Shareholders
- Johnson & Johnson investors were able to exchange less than a quarter of their shares for the consumer split off. The company will update financial guidance next week
- 08/23/2023
|
Kenvue becomes ‘fully independent' after final separation from J&J
- Kenvue Inc. KVUE, +3.67% kicks off life as a fully independent public company Wednesday after completing its separation from Johnson & Johnson JNJ, -0.79%, the company said in a release. J&J accepted an aggregate of 191 million shares of its common stock in exchange for 1.53 billion shares of Kenvue's common stock and now owns 9.5% of Kenvue's outstanding shares.
- 08/23/2023
|
Kenvue stock price forecast: Is this JNJ spin-off a good buy?
- Kenvue (NYSE: KVUE) stock price jumped by more than 3% on Tuesday as investors reacted to the oversubscription of an exchange offer for Johnson & Johnson (NYSE: JNJ). The stock jumped to a high of $23.80, over 6% above the lowest level this year.
- 08/22/2023
|
J&J's Exchange Offer for Kenvue Is Tricky From a Tax Standpoint. What to Do.
- J&J holders who participated in the exchange offer can choose which J&J shares they want to use for their cost basis in Kenvue.
- 08/22/2023
|
J&J spinoff Kenvue to join S&P 500 on Friday
- Johnson & Johnson (NYSE:JNJ)'s consumer health spinoff Kenvue will replace Advance Auto Parts in the S&P 500 index effective Friday, August 25, the index announced. This comes after J&J offered to exchange its shares in Kenvue for shares of J&J in a split-off exchange that expired last Friday.
- 08/22/2023
|
Kenvue Will Join the S&P 500 Friday. It Could Boost the Stock.
- The action could lift shares of Kenvue, but Johnson & Johnson stock could come under pressure due to index selling.
- 08/21/2023
|
J&J spinoff Kenvue to replace Advance Auto Parts on the S&P 500
- Kenvue Inc. KVUE, +0.13%, the maker of Tylenol and Benadryl, will replace auto-parts retailer Advance Auto Parts Inc. AAP, -2.33% on the S&P 500 Index SPX, +0.69%, S&P Dow Jones Indices said on Monday. The move takes hold before the opening of trading on Friday.
- 08/21/2023
|
KVUE Stock Alert: Johnson & Johnson Reveals Results of Kenvue Exchange Offer
- Kenvue (NYSE: KVUE ) stock is gaining modestly higher on Monday on the results of a share exchange with Johnson & Johnson (NYSE: JNJ ), from which Kenvue was spun off. Specifically, Johnson & Johnson revealed that the exchange offer was oversubscribed.
- 08/21/2023
|
Market Movers August 21, 2023: Tupperware, Kenvue, Earthstone Energy
- Citi (C) is considering a structure overall that would split its Institutional Clients Group into three separate business segments, according to a report from the Financial Times. The proposed move would split the Institutional Clients Group into investment and corporate baking, global markets, and transaction services.
- 08/21/2023
|
J&J says Kenvue tender offer was oversubscribed, expects 23.8% of tendered shares will be exchanged
- Johnson & Johnson JNJ said Monday that 802.7 million shares of its common stock were validly tendered and not validly withdrawn in a Kenvue Inc. KVUE tender offer that expired at midnight Friday. The tender offer was oversubscribed, as expected, and J&J intends to accept about 191 million of the tendered shares in exchange for the 1.53 billion shares of Kenvue's common stock that it owned.
- 08/21/2023
|
J&J Exchange Offer for Kenvue Is Substantially Oversubscribed
- Johnson & Johnson investors who elected to participate in the swap will see just 23.8% of their shares converted into Kenvue stock
- 08/21/2023
|
Kenvue Split-Off: Still Undecided? 3 (And A Half) Aspects To Consider
- Johnson & Johnson will split off its majority stake in Kenvue Inc. - current shareholders have until August 18 (Friday) to decide whether to exchange some or all of their Johnson & Johnson shares. In this article, I explain the main reasons for my decision not to participate in the offering - despite a 7% discount and a 25% higher dividend yield. I also share why I decided not to exchange even a portion of my Johnson & Johnson shares - after all, it wasn't an all-or-nothing offer.
- 08/16/2023
|
A New Stock Is About to Join the S&P 500. Does History Show That Buying It Now Could Pay Off?
- Johnson & Johnson spinoff Kenvue will soon be added to the S&P 500. History has shown that stocks often enjoy a boost after the announcement of their addition to the S&P 500.
- 08/16/2023
|
J&J Investors Need to Decide Soon If They Want Kenvue Stock
- The $40 billion exchange offer for shares of Kenvue expires Friday but brokerage firms want retail investors to make their instructions before then
- 08/14/2023
|
Is Kenvue Stock a Buy After Earnings?
- Kenvue recently held its first earnings call as a standalone public company. While financial results are limited, the stock trades for a noticeable discount to its peers.
- 08/11/2023
|
KVUE Stock Alert: Kenvue to Join the S&P 500
- Kenvue (NYSE: KVUE ) stock is a hot topic among traders on Thursday following news that it will be added to the S&P 500 . Investors will note that Kenvue is joining the S&P 500, as well as the S&P 100, as Johnson & Johnson (NYSE: JNJ ) is splitting off a minimum of 80.1% of KVUE stock that it owns.
- 08/10/2023
|
J&J spinoff Kenvue set to join S&P 500 index
- Kenvue is set to make its debut in the S&P 500 index, a move confirmed by S&P Dow Jones Indices following the impending completion of Johnson and Johnson's exchange offer for Kenvue stock. The inclusion comes after Kenvue's nearly $47 billion initial public offering by Johnson and Johnson in May.
- 08/10/2023
|
Kenvue Will be Added to S&P 500 After J&J Exchange Offer
- The Johnson & Johnson spinoff is the consumer health company that makes Listerine and Tylenol.
- 08/09/2023
|
Kenvue, the J&J spinoff, will join the S&P 500 index
- Kenvue Inc., maker of Tylenol, Benadryl and other household names in health-care products, is joining the S&P 500, index provider S&P Dow Jones Indices said late Wednesday.
- 08/09/2023
|
Johnson & Johnson Plans Exchange Offer for Kenvue
- Johnson & Johnson ( JNJ , Financial) has recently announced its intention to split off Kenvue Inc. ( KVUE , Financial) shares through an exchange offer. This move marks the next step in the separation from the parent company.
- 08/07/2023
|
Dividend Investors in This Unique Stock-Split Stock Have a Decision to Make
- Johnson & Johnson is splitting off its consumer healthcare business to shareholders. They can exchange all, some, or none of their shares for Kenvue stock.
- 07/25/2023
|
Johnson & Johnson Offers Exchange for Shares of Spinoff Kenvue
- Johnson & Johnson offers its shareholders the choice to exchange its shares for Kenvue's, the consumer health company it spun off just two months ago.
- 07/24/2023
|
Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
- J&J said it received a waiver that dismisses the share lockup period associated with Kenvue's initial public offering in May.
- 07/24/2023
|
Johnson & Johnson launches share exchange offering for Kenvue
- Johnson & Johnson (NYSE:JNJ) (J&J) has launched a share exchange offer for its former consumer health business Kenvue which completed its initial public offering in May. Shareholders of J&J can opt to exchange some or all of their shares for Kenvue stock at a 7% discount, subject to certain conditions, the company announced on Monday.
- 07/24/2023
|
J&J begins share exchange offer for consumer health spin-off Kenvue
- Johnson & Johnson said on Monday it had launched an exchange offer for its investors to exchange J&J's shares with those of its consumer health unit Kenvue.
- 07/24/2023
|
Johnson & Johnson to spin off at least 80.1% of Kenvue shares in an exchange offer
- Johnson & Johnson JNJ, +1.07% said Monday it is planning to spin off at least 80.1% of its shares of Kenvue Inc. KVUE, -2.04% through an exchange offer. The consumer goods and healthcare giant announced its intention to launch an exchange offer for the separation of Kenvue, its consumer health business which went public in May, when it reported earnings last week.
- 07/24/2023
|
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
- Thibaut Mongon's remarks follow Kenvue's second-quarter earnings beat, which was fueled by resilient demand for brands like Band-Aid, Tylenol and Aveeno.
- 07/21/2023
|
Kenvue CEO talks earnings, strong demand, stock: 'We are focused on the power of our portfolio'
- Yahoo Finance health care reporter Anjalee Khemlani spoke with Kenvue CEO Thibaut Mongon about the company's latest earnings report, the outlook for growth, product portfolio, and Johnson & Johnson.
- 07/20/2023
|
Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
- J&J owns nearly 90% of Kenvue shares and plans to reduce its stake in the company through an exchange offer that could launch "as early as the coming days."
- 07/20/2023
|
Is Johnson & Johnson Giving Up on Kenvue (KVUE) Stock?
- One of the more interesting moves in today's market comes from recent spinoff Kenvue (NYSE: KVUE ). Currently, shares of KVUE stock are down around 3% in today's session, as the company reported earnings that beat Wall Street estimates by a rather wide margin.
- 07/20/2023
|
Johnson & Johnson Rips Off the Kenvue Band-Aid
- A surprisingly early distribution and a stretched valuation hit J&J's consumer health arm hard.
- 07/20/2023
|
Stock movers July 20, 2022: Johnson & Johnson, Kenvue, and Abbott Labs
- Johnson & Johnson, Kenvue, and Abbott Labs posted second quarter results that topped analyst estimates. Yahoo Finance Live anchors break down the market reaction to the report.
- 07/20/2023
|
J&J spinoff Kenvue CEO on first full quarterly earnings results since IPO
- Thibaut Mongon, Kenvue CEO, joins 'Squawk on the Street' to discuss the company's quarterly earnings results, what Mongon is seeing from the consumer, and much more.
- 07/20/2023
|
Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
- J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff's business for the time being.
- 07/20/2023
|
Tylenol, Benadryl parent Kenvue tops earnings expectations, amid strength in pain care, cold and flu product demand
- Tylenol, Benadryl and Listerine brands parent Kenvue Inc. KVUE, +0.77% reported Thursday second-quarter profit and revenue that beat expectations, provided an upbeat full-year outlook and initiated a dividend. The household consumer brands company's stock was will inactive in the premarket.
- 07/20/2023
|
Kenvue quarterly sales rise on strong demand for self-care products
- Kenvue on Thursday posted a rise in quarterly sales thanks to strong demand for its self-care and skincare brands such as Tylenol and Neutrogena.
- 07/20/2023
|
3 Healthcare Stocks to Buy as the Market Gets Defensive
- With so much concern about the Federal Reserve and its decision-making implications for forward market trends, investors may do well targeting healthcare stocks. Fundamentally, the underlying sector represents a critical need.
- 07/18/2023
|
IPO Market Showing Signs Of Life, Drawing Second-Half Optimism On Wall Street
- The last 18 months have been like an ice age for investment bankers brokering deals and young business owners looking to tap extra capital. Several successful recent IPOs may foster green shoots for firms looking to trade on the secondary markets. While credit markets remain tight and as fears of a global economic slowdown persist, signs are there that the next few quarters could feature some prominent ventures going public.
- 07/14/2023
|
Like shoppers, IPO investors are demanding discounts and showing price sensitivity
- IPO investors, much like shoppers in the current inflationary environment, are demanding clear discounts and demonstrating sensitivity to price and valuations, according to Renaissance Capital.
- 06/30/2023
|
7 Up-and-Coming Stocks to Buy for the Next Decade
- In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios.
- 06/29/2023
|
Kenvue to Announce Second Quarter 2023 Results on July 20, 2023
- SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced financial results for the second quarter ending July 2, 2023, will be released before market open July 20, 2023.
- 06/06/2023
|
1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
- Johnson & Johnson offers a higher dividend yield. It backs that payout with an elite financial profile.
- 06/04/2023
|
Kenvue's stock hits fresh post-IPO lows as Tylenol parent company receives tepid reviews from analysts
- Shares of Kenvue Inc. plumbed new lows after Wall Street analysts started coverage of the consumer household-brands company and Johnson & Johnson spinoff with halfhearted ratings, saying bullish fundamentals have already been priced in.
- 05/30/2023
|
Kenvue is a “show me story” after strong start following J&J spinoff
- UBS analysts initiated coverage of Kenvue Inc (KVUE), the recent spinoff of Johnson & Johnson (NYSE:JNJ)'s consumer brand segment, with a ‘Neutral' rating and a 12-month target price of $28 per share, saying the company is well positioned to deliver sustainable mid-single-digit organic revenue growth over the medium term. “With much of the low-hanging fruit from a valuation perspective captured following the +20% performance since IPO, we think KVUE has become more of a ‘show-me story' and the direction of the stock will depend on estimate revisions from here,” the analysts wrote.
- 05/30/2023
|
7 Consumer Stocks to Buy and Hold for the Long Haul
- When it comes to building a strong portfolio, it's wise to include some of the best long-term consumer stocks. In fact, there are two key reasons for this.
- 05/29/2023
|
Kenvue Just IPO'd, but Is the Stock a Buy?
- Kenvue is now independent of Johnson & Johnson (sort of). It needs to demonstrate that nothing important has changed since the spinoff.
- 05/19/2023
|
2 Dividend Stocks to Double Up On Right Now
- Falling share prices have pushed up the dividend yields on several high-quality companies. Johnson & Johnson currently yields around 3%.
- 05/17/2023
|
Kenvue Has Gone Public: Should You Buy the Stock?
- Shares of Kenvue went public last week as Johnson & Johnson spun off its consumer health business. The new company markets some strong brands, including Tylenol, Nicorette, Motrin, and many others.
- 05/16/2023
|
J&J Kenvue Spinoff Aims To Give Investors A Healthy Return
- This year hasn't been the most active when it comes to initial public offerings, but Johnson & Johnson NYSE: JNJ spinoff Kenvue Inc. NYSE: KVUE set a bar, of sorts, with the biggest IPO since Rivian Automotive Inc.'s NASDAQ: RIVN ill-fated debut in November 2021.
- 05/09/2023
|
U.S. IPO Weekly Recap: Kenvue And ACELYRIN Fire Up The IPO Market, Raising A Combined $4.3 Billion
- The month of May started off with two large IPOs, Kenvue and ACELYRIN. Two blank check IPOs also priced this past week.
- 05/07/2023
|
Kenvue: A Look At The Johnson Spinoff
- Kenvue Inc. has been spun off from Johnson & Johnson in a rather large IPO. The spinoff was well-received by the market, being the world's largest pure-play consumer health play.
- 05/05/2023
|
ETFs to Bet on the Successful Debut of Kenvue
- Kenvue is the world's largest pure-play consumer health company by revenue, and makes well-known products, including Tylenol, Neutrogena, Listerine, Johnson???s', Band-Aid, Aveeno, Zyrtec and Nicorette.
- 05/05/2023
|
Kenvue stock slips on second day of trading
- Yahoo Finance Live's Julie Hyman discusses the decline in stock for Kenvue.
- 05/05/2023
|
Kenvue CEO looks to brand, product innovation to drive growth after IPO
- Kenvue CEO Thibaut Mongon said the spinoff's portfolio of brands, which includes Band-Aid, Tylenol and Neutrogena, has "ample opportunity" to grow.
- 05/05/2023
|
Kenvue Stock Surges On Trading Debut
- Kenvue Inc. is defensive and resilient to macro shocks. The company owns a portfolio of well-established brands.
- 05/05/2023
|
J&J's Kenvue: Unlocking Value in a Stagnant Market
- 2023 has been a pretty slow year as far as initial public offerings go, but pharmaceutical giant Johnson & Johnson ( JNJ , Financial) bucked the trend on Thursday by offering its consumer health division Kenvue (KENV) as an IPO. Priced at about $22 per share and set to raise approximately $3.8 billion for J&J, the IPO values the new pure-play consumer health company at a total of $41 billion.
- 05/04/2023
|
Johnson & Johnson Spinoff Kenvue Valued at $41 Billion in IPO
- Johnson & Johnson's consumer healthcare spinoff has made the biggest U.S. initial public offering (IPO) since 2021. Kenvue, which includes Band-Aid and several other well-known consumer brands that had been part of Johnson & Johnson, raised $3.8 billion in an IPO that valued it at $41 billion Thursday (May 4), CNBC reported Thursday.
- 05/04/2023
|
Kenvue IPO: Profitable Company, Expensive Stock
- At its expected valuation, KVUE looks fully valued and does not provide investors with much upside potential.
- 05/04/2023
|
J&J's consumer health spinoff Kenvue begins trading at $25.53 per share
- J&J's consumer health IPO Kenvue opens to the NYSE.
- 05/04/2023
|
Kenvue stock opens 16% above IPO, valuing the company at $47.7 billion
- Kenvue Inc. shares KVUE, +16.16% were cheered in their Wall Street debut Thursday, as the Johnson & Johnson JNJ, -0.55% spinoff, with consumer brands including Tylenol, Band-Aid and Listerine, saw it's stock open 16.0% above its initial public offering price. Kenvue raised $3.8 billion as it said late Wednesday that it sold 172.8 million shares in the IPO, up from previous expectations of 151.2 million shares, at $22 a share, which was at the higher end of the expected pricing range of between $20 and $23 a share.
- 05/04/2023
|
J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
- Kenvue's debut is the biggest U.S. IPO since EV maker Rivian went public in 2021.
- 05/04/2023
|
J&J spinoff Kenvue goes public
- Kenvue CEO Thibaut Mongon joins 'Squawk on the Street' to discuss the company's IPO, which is the largest U.S. IPO since November 2021.
- 05/04/2023
|
Johnson & Johnson spinoff Kenvue prices largest IPO since 2021
- Johnson & Johnson (NYSE:JNJ)'s consumer health unit Kenvue Inc just priced the biggest US IPO since 2021, in a spot of welcome news for capital markets. The spinoff is expected to achieve a valuation of $47 billion when it debuts on the NYSE on Thursday, with shares priced at $22 apiece but expected to open roughly 14% above that.
- 05/04/2023
|
KVUE Stock Alert: 10 Things to Know as Kenvue Starts Trading
- Kenvue (NYSE: KVUE ) stock is set to start trading today as the company completes its spinoff from Johnson & Johnson (NYSE: JNJ ). Let's go over all of the details investors need to know about Kenvue going public today below!
- 05/04/2023
|
J&J Consumer-Health IPO Stock Kenvue to Raise $3.8 Billion
- Kenvue, which owns brands including Tylenol, Band-Aid, and Neutrogena, will begin trading Thursday. Shares were priced higher than an earlier range.
- 05/04/2023
|
Johnson & Johnson's Kenvue IPO to command valuation of more than $40 billion in biggest public debut since 2021
- A unit of Johnson & Johnson is headed for the biggest initial public offering in more than a year after its shares were priced near the top of the expected range Wednesday evening.
- 05/03/2023
|
KVUE Stock: Should You Buy Into the Kenvue IPO?
- Johnson & Johnson (NYSE: JNJ ) will spin out its consumer health unit as Kenvue tomorrow, May 4. The stock will trade on the NYSE under the symbol KVUE.
- 05/03/2023
|
J&J's Kenvue spinoff to hit IPO market this week in the biggest deal since late 2021
- Johnson & Johnson's consumer health company Kenvue is expected to hit the initial public offering market this week and mark the largest deal since late 2021.
- 05/01/2023
|
KVUE Stock IPO: When Does Kenvue Go Public? What Is the Kenvue IPO Price Range?
- One of the season's most hotly anticipated initial public offerings (IPOs) is about to hit the market. Kenvue is a planned spinoff from Johnson & Johnson (NYSE: JNJ ), and the company is set to begin trading soon.
- 05/01/2023
|
US IPO Weekly Recap: J&J Spin-Off Kenvue Launches Billion-Dollar Deal In A 1 IPO Week
- The week's news was led by J&J's consumer health unit Kenvue, which set terms for its $3.3 billion listing on Monday. Six IPOs submitted initial filings this past week.
- 04/30/2023
|
IPO Update: Kenvue Seeks $3.25 Billion IPO
- IPO Update: Kenvue Seeks $3.25 Billion IPO.
- 04/25/2023
|
Does Johnson & Johnson's Kenvue IPO signal signs of life for US IPO market?
- Are signs of life emerging from the moribund IPO market? If Johnson & Johnson (NYSE:JNJ)'s corporate advisors are correct, then, yes, possibly.
- 04/25/2023
|
Johnson & Johnson spinoff Kenvue receives IPO value of $40 billion
- #Johnson&Johnson The Yahoo Finance Live team discusses the rise of Johnson & Johnson stock after a steady decline the past year, amid controversy regarding some products.
- 04/24/2023
|
Johnson & Johnson aims to raise $3 billion in Kenvue IPO
- Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50.
- 04/24/2023
|
Kenvue ‘will certainly be a beacon and a bellwether' for corporate spinouts, professor says
- Columbia University Healthcare Policy Professor Meghan Fitzgerald joins Yahoo Finance Live to discuss the expectations for health care earnings, health care trends, investor sentiment, and the outlook for Johnson & Johnson's consumer health company Kenvue.
- 04/24/2023
|
U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers
- U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers.
- 04/24/2023
|
Johnson & Johnson plans to spin off consumer health business as Kenvue
- Yahoo Finance health care reporter Anjalee Khemlani joins the Live show to discuss Johnson & Johnson's plans to spinoff its consumer health business.
- 04/18/2023
|
Johnson & Johnson looking at spinning off consumer health business as Kenvue
- #Johnson&Johnson Yahoo Finance's Anjalee Khemlani joins the Live show to discuss news that Johnson & Johnson is working toward spinning off its consumer health business as Kenvue.
- 04/18/2023
|
Johnson & Johnson Preps for Kenvue Spinoff While Noting Strong Q1 in OTC
- As Johnson & Johnson readies for the separation of its consumer health division later this year into the consumer-focused company called Kenvue, the healthcare giant's first quarter was marked by continuing moves away from COVID-era focuses and into areas like robotic surgery.
- 04/18/2023
|
U.S. IPO Weekly Recap: Small Deals Drive Activity In The IPO Market's Short Week
- Four small issuers began trading this past week. Two small IPOs submitted initial filings.
- 04/07/2023
|
J&J Kenvue spinoff adds slew of banks to its initial public offering roster
- Kenvue Inc., the consumer products spinoff from Johnson & Johnson JNJ, +0.89% , has grown the roster of banks underwriting its initial public offering beyond the two original leads . Goldman Sachs & Co. LLC and JP Morgan, according to a filing on Friday.
- 03/06/2023
|
Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence
- Investing in blue-chip companies that pay dividends and relentlessly focusing on reinvesting the proceeds is a proven strategy for reliable long-term returns. But what about the occasional black swan? Potentially devastating litigation? Overlooked liabilities on the balance sheet? Financial engineering?
- 01/18/2023
|
J&J's Spin-Off Kenvue Lists for IPO in Healthcare Giant Split
- As markets open for the new year, a mega breakup that could shake up the consumer healthcare market is coming down the initial public offering (IPO) pipeline.
- 01/09/2023
|
Kenvue Begins IPO Process As It Seeks To Separate From Johnson & Johnson
- Kenvue has filed to go public as part of its separation process from parent firm Johnson & Johnson. The company sells consumer healthcare and wellness products worldwide.
- 01/07/2023
|
